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ABSTRACT

Study of Inducible Gene Expression in Cell Cultures and in
Microencapsulated Cells Using a Renilla LuciferasQ-Aequorea gfp
Fusion Gene Construct
by

Yong Yu
Doctor of Philosophy, Graduate Program in Anatomy
Loma Linda University, June 2002
Dr. Aladar Szalay, Chairperson

The mifepristone-regulated transcriptional activation system provides a means to
exogenously control gene expression in transformed mammalian cells in a temporal
and spatial fashion. Such a promoter activation system consists of three components:
The first of these is a steroidal inducer drug, mifepristone. This drug binds to the
second component, a chimeric transcription factor complex, consisting of the mutant
human progesterone receptor fused to the yeast GAL4 DNA-binding domain and the
Herpes simplex virus protein VP 16 activation domain. The third component is a
synthetic promoter, consisting of a series of GAL4 recognition sequences upstream of
the adenovirus major late E1B TATA box, linked to a Renilla XwciferasQ - Aequorea
green fluorescent protein (GFP) fusion gene {ruc-gfp). The transcription of the
promoter-marker gene cassette is activated by the mifepristone-bound chimeric
transcription factor complex. The mifepristone-activated gene expression of
luciferase and GFP was monitored by a low light video camera and a UV microscope
respectively. Using this activation system in transiently transfected cells, we

xm

observed a 10-25 fold mifepristone-dose-dependent activation of both luciferase and
GFP expression which lasted up to 38 hours after the initial addition of the inducer
drug, but no induction in cells not treated by mifepristone. Further, to facilitate the
development of the mifepristone-induced transcriptional activation system in cellular
implants for future in vivo studies, we used biocompatible calcium alginate/poly-Llysine (PLL) beads to encapsulate cells, which may provide immune protection for
cells during prolonged cellular transplantation. Using GFP as a marker, we
monitored the growth and proliferation of encapsulated cells in culture dishes over a
long period of time, up to two and a half months. We also showed that the ruc-gfp
fusion gene expression in encapsulated mammalian cells could be regulated in a
mifepristone dose-dependent manner, with induction kinetics similar to those in nonencapsulated cells in culture. From these results, we conclude that the mifepristoneregulated ruc-gfp fusion gene expression system may facilitate studies answering
fundamental biological and therapeutic questions experimentally. In addition, real
time monitoring of regulated gene expression from alginate-encapsulated cells may
provide a useful tool for designing cellular implantation-based protein therapy for
clinical applications.

xiv

CHAPTER ONE
INTRODUCTION
The development of recombinant DNA technology along with the advances of
modem cell biology, molecular biology, and biochemistry have helped the emergence
and development of a new method of disease treatment strategy, namely, gene
therapy. Although the original meaning of the term “gene therapy” emphasizes the
delivery of genetic material to the cells of an organism to replace a defective or
missing gene, in recent years, “gene therapy” has been used more broadly as a general
term to describe any therapy that utilizes recombinant DNA technology for disease
prevention or treatment using gene-based, recombinant protein-based, or transformed
cell-based therapeutic systems.
In general, gene therapy strategies can be divided into two major categories: viralbased and non-viral based. In viral-based therapies, the transgenes are delivered to
mammalian cells using viral vectors such as adenovirus (Kozarsky and Wilson 1993;
Vorburger and Hunt 2002), adeno-associated virus (Smith-Arica and Bartlett 2001),
retrovirus (Hu and Pathak 2000), lentivirus (complex retrovims), Vaccinia vims
(Carroll and Moss 1997; Broder and Earl 1999), alphavirus (Schlesinger 2001),
simian virus-40 (SV-40) (Strayer 2000), coronavims (Enjuanes et al. 2001), and
herpes virus (Lachmann and Efstathiou 1999; Delecluse and Hammerschmidt 2000;
Burton et al. 2001). In non-viral based therapies, naked plasmid DNA (Liu and
Huang 2002), liposome- or artificial polymer-encapsulated plasmid DNA (Nicolau
and Cudd 1989; Madsen and Mooney 2000; Fenske et al. 2001) and protein (Trif et
al. 2001), mRNA (Bettinger and Read 2001), purified recombinant proteins (Russell
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and Clarke 1999), and ex vzvo-modified cells (Jones and Thomson 2000; Bhatia and
Porter 2001) are used as carriers to deliver transgenes to the organism for therapeutic
protein expression and disease treatment.
There are several factors that are crucial for the success of a gene therapy. They
are: (1) regulated expression or controlled release of the therapeutic protein; (2)
efficient and targeted delivery of the therapeutic protein to the appropriate cells
without harm to normal tissues; (3) a stable system with minimal host immune
rejection, which allows for prolonged treatment. Firstly, the non-physiological
constitutive expression of exogenous proteins may provide a high level of
concentration, although this may be harmful to normal cellular physiology in the long
term. In many cases, the success of the therapy is highly dependent on the dose of the
delivered proteins (Low 1993; Schmidt et al. 1995; Naffakh and Danos 1996; AghaMohammadi and Lotze 2000a; Jeschke et al. 2001). To exogenously regulate the
levels of therapeutic proteins, naturally occurring or synthetic, inducible promoters
have been successfully used to express the transgenes (Clarkson 1997; Harvey and
Caskey 1998; Agha-Mohammadi and Lotze 2000b). Secondly, in addition to
regulating the level of therapeutic protein expression, another factor that will greatly
improve the efficiency of therapy is targeted transgene delivery, targeted transgene
expression, and targeted delivery of therapeutic proteins (Curiel 1999; Peng 1999;
Schaffer and Lauffenburger 2000). A fusion of therapeutic proteins to tissue specific
antibodies (Strom et al. 1990; Haber 1992; Xiang 1999) and linking of transgenes to
tissue-specific promoters (Lu and Steiner 2000; Lee et al. 2001) are two examples of
targeting systems that have been designed to increase the delivery specificity of
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foreign molecular or cellular materials after systemic injections. And thirdly, just as
in organ transplantation, an inevitable challenge for gene therapy is the immune
rejection of non-self foreign molecular and cellular materials. This is particularly
problematic for stable long-term therapies. Several approaches have been used to
overcome this problem. One of them is to genetically or chemically modify the
foreign materials to decrease immune rejection. Expression of nonclassical human
leukocyte antigens on xenogeneic cells, for example, will dramatically reduce natural
killer cell-mediated cytotoxicity by the host and increase the survival of the implanted
cells (Carosella et al. 1999; Lopez-Botet et al. 2000). In addition to genetic or
chemical modifications, another approach to reduce host immune rejection is to
encapsulate the foreign materials, such as cells, in biocompatible polymers (Han et al.
2000; Uludag et al. 2000; Cascone et al. 2001). The application of these polymers not
only shields the foreign cells from the components of the host immune system but
also provides a stable environment that allows the free passage of therapeutic
proteins, nutrients, and wastes. A successful gene therapy strategy can be developed
only when all three of the above issues have been taken into consideration.
In this study, we developed a system which addressed two of the above three
issues, and may help in designing efficient and effective gene therapy protocols in the
future, namely (a) the exogenous regulation of transgene expression and (b) the
microencapsulated-cell systems for immuno-protection. More specifically, we
describe for the first time the capability of monitoring exogenously regulated gene
expression using a mifepristone-induced promoter activation system in real time.
Non-invasive imaging of gene expression is made possible using the light-emitting
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fusion protein consisting of Renilla luciferase and Aequorea green fluorescent protein
(Ruc-GFP). This fusion product allows both qualitative and quantitative measurement
of transgene activities. Also, we describe for the first time the monitoring of
controlled protein expression in alginate-microencapsulated cells in real-time using
the Ruc-GFP fusion protein.
In the following sections we provide a brief review of inducible promoter systems
for regulated gene expression, of mammalian cell encapsulation in biocompatible
polymers, and of Rue and GFP.
Review of Inducible Promoter Systems
Inducible Promoter Systems for Regulated Gene Expression in Eukaryotic Cells
Many naturally occurring ligand-dependent transcriptional regulatory systems
have been reported and well studied. One of the best examples is hormone-mediated
gene expression regulation. Steroid hormones such as estrogen, glucocorticoids, and
progesterone, secreted by endocrine cells into the blood circulation travel to and enter
cells at a distant location. The hormones then bind to their respective receptors, and
the hormone/receptor complex interacts with specific DNA sequences to activate or
repress transcription (Almawi et al. 1996). With the development of synthetic
hormone analogues, one can mimic and manipulate the regulatory effect of these
hormones through exogenous injection of these analogues (Curran and Wagstaff
2001). Other examples of naturally occurring transcriptional regulation systems in
eukaryotic cells include the heat-induced expression of heat shock proteins (Tanguay
1988; Lohr et al. 2001; Vivinus et al. 2001), the stress-induced expression of the
multidrug resistance gene, mdrl (Kohno et al. 1989; Chin et al. 1990; Uchiumi et al.
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1993; Walther et al. 2002), and the glucose-regulated protein gene, grp (Gazit et al.
1995).
Although the naturally occurring promoters have been used initially to regulate
gene expression in mammalian cells, the high basal transcriptional levels in the
absence of inducing signals limit their application in gene therapy (Vourc'h et al.
1989; Yarranton 1992). To overcome this problem, synthetic promoters have been
designed that can be activated by chimeric transcription factors derived from
functional domains of prokaryotic, eukaryotic, and viral origins. Two basic
components are required for designing artificial inducible promoter systems: First, an
exogenously added chimeric transcriptional factor able to bind specifically to the
inducible promoter sequence, which cannot be bound and activated by endogenous
transcriptional factors. The chimeric transcription factor should also exhibit a
minimal level of immunogenicity. Second, an exogenously added chemical drug is
needed to bind to the transcriptional factor and reversibly activate the inducible
promoter. This drug should be able to be delivered orally, to readily enter cells, and
to be non-toxic to the host. In an ideal inducible promoter system, transcription
should be at a minimal level in the absence of the drug. However, the addition of the
drug should trigger a robust dose-depend activation of gene expression. Regulated
gene expression from inducible promoters has been successfully demonstrated in
eukaryotic cells and animals using ecdysone (No et al. 1996; Saez et al. 2000),
tetracycline and doxycycline (Shockett et al. 1995; Chen et al. 1998; Saitoh et al.
1998), rapamycin (FK506) (Ho et al. 1996a; Rivera et al. 1996; Liberies et al. 1997),
IPTG (Hu and Davidson 1987), and mifepristone (Wang et al. 1994; Delort and
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Capecchi 1996) as the inducer drugs. As noted by Senner et al. (2001), the selection
of the most appropriate system for regulated transgene expression depends on the
experimental procedures, the application, and the gene to be regulated. Each system
has advantages and disadvantages, which should be taken into consideration when
selecting inducible promoter systems.
The use of natural steroid hormones and receptors for regulated gene expression
from inducible synthetic promoters is complicated by the fact that endogenous
hormones may also bind the synthetic promoter and interfere with transcriptional
activation. Ecdysone (Ec, also known as p-ecdysterone and 20-hydroxyecdysone) is
a Drosophila steroid hormone (Fig. 1.1). Christopherson et al. (1992) demonstrated
that Ec specifically interacts with Ec receptor (EcR), which cannot be bound by
endogenous human hormones. No et al. (1996) made further modifications in both
the transcriptional factor constructs and the inducible synthetic promoter in the
reporter construct to generate the currently used version of the Ec-regulated promoter
system. The chimeric transcriptional factors are provided as two separate proteins on
two different plasmid constructs. One construct encodes the retinoid X receptor
(RXR), which is the mammalian homolog of Drosophila Ultraspiracle protein (USP),
linked to either a constitutive CMV promoter or a tissue specific promoter. The
second construct contains a fusion gene, encoding a mutant EcR and the Herpes
simplex virus (HSV) VP 16 transcriptional activation domain, also linked to either a
CMV promoter or a tissue specific promoter. Simultaneous expression of both
proteins in the same cells will not form the active chimeric transcriptional activator
complex unless the inducer drug Ec is added (Yao et al. 1993). The synthetic
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Figure 1.1. The chemical structures of ecdysone and muristerone A. Ecdysone
(Ec; a phytoecdysteroid) is an insect molting hormone. Muristerone A (murA) is an
analog of Ec. The lipophilic Ec and murA molecules efficiently penetrate all tissues,
including the brain, and have short half-lives in vivo. These properties of Ec and
murA allow rapid and potent induction of gene expression, making them desirable as
inducer drugs, which are rapidly cleared from the circulation.
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inducible promoter construct consists of four copies of a 29-base-pair DNA sequence
of a mutant ecdysone response element fused to a minimal promoter able to drive the
expression of the downstream target gene. In the presence of the inducer Ec, the Ecbound-EcR-VP16 will form a heterodimer with RXR to produce the active
transcriptional factor complex, which will then bind to the synthetic promoter to
activate the transcription of the target gene. The Ec-regulated promoter system has
both a low basal activity and an up-to-20,000-fold induction of transcriptional
activation in cell culture experiments (No et al. 1996). The regulated expression of
many proteins, including the expression of chloramphenicol acetyltransferase (CAT),
p-galactosidase (P-gal), luciferases (No et al. 1996; Kams et al. 2001), enhanced GFP
(Luers et al. 2000), human nerve growth factor, NGF (Patrick et al. 2001), PTEN
tumor suppressor (Stolarov et al. 2001), p53 (Abeysinghe et al. 2001), and Ras GTPbinding proteins (Plows et al. 2002), were successfully demonstrated in cell cultures
and in live animals. The disadvantage of the system is that it requires the over
expression of RXR, which may interfere with normal signal transduction pathways
that are responding to retinoid and thyroid hormones (Constantino et al. 2001).
Inducer drugs other than Ec, such as muristerone A (No et al. 1996; Patrick et al.
2001), a synthetic analog of Ec, and other ecdysteroids, such as ponasterone A (Saez
et al. 2000), have also been successfully applied to induce transcriptional activation
from the same inducible system. It was shown, however, that muristerone A and
ponasterone A may interfere with cytokine signaling and ultimately the growth and/or
survival of mammalian cells (Constantino et al. 2001). Therefore, less toxic Ec
analogs may need to be synthesized.
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The tetracycline (tet)-induced regulatable system is another inducible promoter
system that has been widely used to regulate transgene expression in mammalian
cells. Tetracycline (Fig. 1.2) or its derivative doxycycline, dox (Fig. 1.2), is used as
the inducer drug. The tet-regulated systems are divided into two groups: allosteric
off-switch (tet-off), and allosteric on-switch (tet-on), which are commercially
available as Tet-Off™ and Tet-On™ (Expression Systems & Cell Lines, Clontech,
Palo Alto, CA). Both utilize the two regulatory elements derived from the
Escherichia coli tet-resistance operon: the tet repressor protein (TetR) and the tet
operator DNA sequence (tetO).
In the two-plasmid tet-off system (Fig. 1.3), the chimeric transcriptional activator
plasmid carries a fusion gene between the TetR sequence and the sequence of HSV
VP 16 transcriptional activation domain. This fusion gene is under the control of
CMV promoter. The inducible synthetic promoter in the reporter plasmid construct
consists of tetO fused to a minimal promoter upstream of the reporter transgene
sequence. In the absence of tetracycline, the chimeric transcriptional activator can
bind to the tetO sequences in the inducible promoter and allow transcription. In the
presence of tetracycline, however, the chimeric transcriptional activator-tet complex
can no longer bind to the tetO sequences and the transcription is therefore turned off
(tet-off). A low basal activity and an up to 100,000-fold transcriptional activation
have been reported in cell culture experiments when tetracycline is withdrawn from
the culture medium (Gossen and Bujard 1992). Transcriptional activation of the tetoff system has also been demonstrated in animals. Regulated expression of signal
transduction pathway genes, oncogenes, and reporter genes has been successfully
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Figure 1.2. The chemical structures of tetracycline and doxycycline.
Tetracycline (tet) and doxycycline (dox) are broad-spectrum antibiotics that inhibit
bacterial growth by reversibly binding to the 30S ribosomal subunit and inhibiting
protein synthesis. Tet is prepared from the cultures of certain Streptomyces spp. Dox
is a synthetic derivative of tet.
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demonstrated in animal studies using the tet-off system (Saez et al. 1997;
Gingrich and Roder 1998; Jaisser 2000). In addition to the two-plasmid system,
Schultze et al. (1996) also demonstrated tight control of gene expression in
transgenic mice using a single-plasmid tet-off system with the chimeric
transcriptional activator expression cassette and the inducible promoter-transgene
fusion construct in cis configuration. The disadvantage of the tet-off system is
that the continued presence of tetracycline is required to maintain the “off’ state,
which may not be desirable for long-term applications.
The principle of the tet-on (reverse tet) system (Fig. 1.3) relies on the isolation of
TetR mutants from E. coli that require the presence of tetracycline to allow the
binding of the TetR to the tetO sequences (Gossen et al. 1995). The tet-on system is a
two-plasmid system. The chimeric transcription activator plasmid consists of a fusion
between the mutant TetR gene and the sequence encoding the viral VP 16 activation
domain under the control of the CMV promoter. The second plasmid carries the
sequence of the target gene under the control of an inducible promoter, which
contains seven copies of tetO fused to the human CMV immediate early minimal
promoter. Regulated gene expression from the two-plasmid tet-on system has been
demonstrated in transgenic mice (Kistner et al. 1996; Puttini et al. 2001). For
example, long-term regulated delivery of erythropoietin from implanted cells has
been shown in live mice (Bohl et al. 1997). The limitation of the tet-on system is the
residual binding of TetR to tetO in the absence of tetracycline. To address this
problem, further technical improvements were conducted to reduce the basal
expression level without altering the inducibility of the system. Zhu et al. (2001)
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r

Figure 1.3. Tetracycline (or doxycycline)-induced inhibition or activation of gene
expression using “tet-off’ and “tet-on” (reverse tet) systems, respectively. In the
“tet-off ’ system, without tet or dox, the tet repressor of the chimeric transcriptional
activator can bind to the tetO sequences in the synthetic promoter of the reporter
plasmid, and the VP 16 transcriptional activation domain of the chimeric
transcriptional activator can activate gene expression from the minimal CMV
promoter. In the presence of tet or dox, the chimeric transcriptional activator cannot
bind to the synthetic promoter and therefore there is no activation of gene expression.
In the “tet-on” (reverse tet) system, on the other hand, the mutant chimeric
transcriptional activator will bind to the synthetic promoter and activate gene
expression only in the presence of tet or dox.
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successfully utilized a tetracycline-controlled transcriptional silencer (tTS), a fusion
protein containing the Tet repressor and the KRAB-AB domain of the kid-1
transcriptional repressor, to tighten the control of tet-induced gene expression in
transgenic mice.
The third type of regulated gene expression system is based on chemical
dimerizers and their binding proteins. These dimerizers, such as rapamycin (SigmaAldrich, St. Louis, MO; Fig. 1.4), were originally used as immunosuppressants by
dimerizing and inactivating cellular proteins that are involved in T cell activation in
the immune response pathways (Sigal and Dumont 1992). The cellular protein with
which rapamycin interacts is immunophilin FK506-binding protein 12 (FKBP12).
Similar to rapamycin, FK506 is another drug with an immunosuppressant function
(Inamura et al. 1988; Bierer et al. 1991). Using synthetic homodimers of FK506
(FK1012 or AP1510; Fig. 1.4; Ariad, Cambridge, MA), any two proteins with the
FKBP domains can be brought together by the same homodimer (Spencer et al.
1993). Using heterodimers of FK506 and cyclosporin A (FK-CsA) as a bridge, any
proteins with FKBP domains can interact with proteins containing cyclophilin
domains (Belshaw et al. 1996). Also, a heterodimer between FKBP and the lipid
kinase homolog FKBP12-rapamycin-associated protein (FRAP) can also be formed
through the mediation of rapamycin. Based on this principle, Rivera et al. (1996)
designed an inducible promoter system for regulated gene expression in mammalian
cells and transgenic animals (Fig. 1.5). This system consists of three plasmid
constructs. The first plasmid carries the expression cassette of a fusion gene between
the chimeric ZFHD1 DNA-binding domain (Pomerantz et al. 1995) and three
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Figure 1.4. The chemical structures of the dimerizers rapamycin, FK1012, and
AP1510. Rapamycin (23,27-Epoxy-3H-pyrido(2,lc)(l,4)oxaazacyclohentriacontine) is an analog of the immunosuppressant drug
FK506. It is prepared from the culture of Streptomyces hygroscopicus. FK1012 and
API510 are synthetic homodimers of FK506. These small dimerizer drugs are able to
enter most tissues in the body, including the brain and the fetal circulatory system,
and each has a short half-life in vivo (Clackson 1997).
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Figure 1.5. Transcriptional activation using the rapamycin, FK1012, and
AP1510 dimerizers. In the rapamycin-induced transcriptional activation system, a
yeast GAL4 DNA binding domain (DBD) is fused to the FK506 binding protein
(FKBP), and an HSV VP 16 transcriptional activation domain is fused to the FKBPrapamycin-associated protein (FRAP). Both chimeric proteins are expressed under a
constitutive promoter. Without rapamycin, even though DBD can bind to GAL4
DNA binding sites in the synthetic promoter of the reporter plasmid, no transcription
is activated. When rapamycin is added, rapamycin mediates the formation of
heterodimers between FKBP and FRAP, bringing in the transcriptional activation
domain which activates gene expression. FK1012 and APIS 10 are dimerizers that
induce the activation of gene expression in a similar manner as rapamycin.
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FKBP12 repeats under the control of the CMV promoter. The second plasmid carries
the expression cassette of a fusion gene consisting of the coding sequence of the
FRAP rapamycin-binding domain (FBP) and the coding sequence of the NFkB p65
carboxyl-terminal transactivation domain under the control of the CMV promoter.
The third plasmid is the reporter plasmid carrying a synthetic promoter consisting of
12 copies of ZFHD1-binding sequences and a CMV minimal promoter to control the
expression of the downstream transgene. In the presence of rapamycin, the ZFHD1FKBP(3) can bind to FBP-p65 to form the transcription activator complex. The
binding of the ZFHD1 portion of the complex to the ZFHD 1-binding sequences in the
synthetic promoter of the reporter plasmid will bring in the transcription activation
domain of p65 and activate transcription of the transgene. Using this system, induced
gene expression at levels of 1,000 to 10,000 fold has been demonstrated in cell
culture experiments (Rivera et al. 1996; Pollock et al 2000). Activated gene
expression from this inducible promoter system has also been successfully
demonstrated in mice (Magari et al. 1997; Rivera et al. 1999) and rhesus monkeys
(Ye et al. 1999). The limitation of this system is that rapamycin regulates gene
expression at doses that are immunosuppressive by binding to endogenous FKBP and
FRAP, which restricts its use for long-term therapy. However, this problem has been
resolved by using synthetic analogs of rapamycin that cannot bind to endogenous
FRAP but only to complement mutant FRAPs (Clackson 1997). Similar inducible
promoter systems (Pollock and Rivera 1999) have also been designed using FK1012
(Ho et al. 1996b), API510 (Amara et al. 1997), and FK-CsA (Belshaw et al. 1996) as
inducer drugs.
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The fourth type of regulated gene expression system is based on the binding of
the bacterial lac repressor to the lac operator sequence originally derived from E. coli.
This isopropyl P-D-thiogalactoside (IPTG, Fig. 1.6)-inducible system is based on two
plasmids. The repressor plasmid carries the lac repressor-encoding the lad gene
driven by a eukaryotic constitutive promoter such as the Rous sarcoma virus long
terminal repeat. The reporter plasmid carries the transgene sequence linked to a lac
operator-containing SV40 early promoter-enhancer. Although the IPTG-induced lac
operator-repressor system has mainly been used to induce gene expression in
prokaryotic cells, it was also shown to be functional in mammalian cells (Hu and
Davidson 1987) and in live animals (Wyborski and Short 1991; Wu et al. 1997).
Regulated expression of mammalian signal transduction proteins and reporter
proteins has been reported (Lin et al. 1997). Modifications in the /ac/gene make the
lac operator-repressor system even more suitable for regulated gene expression in
mammalian cells and animals (Fleck et al. 1992; Scrable and Stambrook 1997;
Cronin et al. 2001). Up to 60-fold induction of transgene expression has been
reported in cell culture experiments (Figge et al. 1988). To further increase the
induction level, Hu and Davidson (1990) utilized the human metallothionein-IIA gene
promoter, instead of the SV40 early promoter-enhancer, in the inducible promoter
and integrated the lac operator sequence in the middle of the promoter. An
approximately 100-fold induction over the basal expression level was observed. In
addition to the human metallothionein-IIA gene promoter, the murine 3phosphoglycerate kinase 1 gene promoter (Hannan et al. 1993) and the human
polypeptide chain elongation factor 1 alpha (EF-1 alpha) promoter (Edamatsu et al.
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Figure 1.6. The chemical structure of IPTG. Re-drawn from Johnson and Church
(2000).

23

OH
CH2OH
O

HO

OH

IPTG

24

1997) have also been used for the insertion of the lac operator sequences. They also
showed a low basal level of gene expression in the absence of IPTG and robust
induction of gene expression when IPTG was added. The limitation of the IPTGinduced lac operator-repressor system is that the induction level is significantly lower
than that in ecdysone-, tetracycline- and rapamycin-induced systems, which can reach
expression levels four orders of magnitude above their respective basal activities.
Furthermore, demethylating agents are required for the transcription of the lad gene
in some strains of transgenic animals (Wyborski et al. 1996). Nevertheless, the finetuned dose-dependent induction of gene expression by metabolically stable IPTG
makes the lac operator-repressor system adaptable for regulated gene expression
studies.
Mifepristone-Induced Transcriptional Activation System
The human progesterone receptor (hPR) binds endogenous progesterone and other
hormones. To apply hPR and its hormone ligands to the design of regulated gene
expression systems, a 42 amino acid deletion mutation was introduced at the carboxyl
terminus of hPR so that it no longer was able to bind to endogenous progesterone but
rather only to the synthetic progesterone analog, mifepristone, also known as RU486
or Mifeprex (Fig. 1.7; Vegeto et al. 1992). The original mifepristone-inducible gene
expression systems were described by Wang et al. (1994) and Delort and Cappechi
(1996). The “GeneSwitch” system described by Wang et al. (1994) is a two-plasmid
system, consisting of a chimeric transcriptional activator plasmid and a reporter
plasmid (Fig. 1.8). More specifically, the chimeric transcriptional activator plasmid
carries the expression cassette of a fusion gene encoding the HSV VP 16 transcription
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Figure 1.7. The chemical structure of mifepristone (RU486 or Mifeprex) and
progesterone. Mifepristone is a synthetic analog of progesterone. Mifepristone can
bind to the mutated progesterone receptor ligand binding domain, which is no longer
able to bind endogenous progesterone.
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Figure 1.8. Mifepristone-induced activation of gene expression. The chimeric
transcriptional activator consists of a yeast GAL4 DNA-binding domain (DBD) fused
to a mutant progesterone receptor ligand binding domain (HPR-LBD) and a VP 16
viral transcriptional activation domain. Without mifepristone, the steric hindrance
effect of HPR-LBD prevents the DBD from binding to the GAL4 DNA-binding sites
in the synthetic promoter, and therefore no activation of transcription occurs. In the
presence of mifepristone, on the other hand, the binding of the inducer drug to HPRLBD triggers a conformational change in HPR-LBD and removes the steric hindrance
effect. This allows the subsequent binding of DBD to the GAL4 DNA-binding sites
in the synthetic promoter and the activation of transgene expression by the VP 16
transcriptional activation domain.
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activation domain (residues 411-487) fused to the carboxyl terminus of the yeast
GAL4 DNA-binding domain (residues 1-94) and also to the amino terminus of the
truncated hPR ligand binding domain (hPR-LBD) (residues 640-891). The fusion
activator gene is under the control of the constitutive CMV promoter. Residues 1-94
of the GAL4 DNA-binding domain contain the DNA binding sites, dimerization sites,
and nuclear localization signals. On the reporter plasmid, the inducible synthetic
promoter consists of four copies of the consensus 17-mer GAL4 binding sequences of
yeast origin fused to the adenovirus E1B TATA box minimal promoter which control
the expression of the target gene. In the absence of mifepristone, the chimeric
transcriptional activator is not able to bind to the synthetic promoter to activate target
gene expression. When mifepristone is added, it is believed that the binding of the
inducer drug to the hPR-LBD induces allosteric change in the hPR-LBD and removes
its steric hindrance effect over the GAL4 DNA-binding domain. Therefore, the
GAL4 DNA-binding domain can bind to GAL4 binding sequences in the synthetic
promoter, and the transcription of the target gene is activated by the incoming VP 16
transactivation domain.
The “GeneSwitch” system has been used to express human growth hormone
(Draghia-Akli et al. 2002), lacZ (Wang et al. 1994), erythropoietin (Abruzzese et al.
2000), and transforming growth factor pi (TGFpl) (Wang et al. 1999). However,
since the protein expression analyses in these studies were carried out by Western
blots using cell lysate or by staining using fixed samples, it is virtually impossible to
follow the induction kinetics in the same group of cells over a period of time. In this
study, we used Renilla luciferase and GFP as living markers to non-invasively
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visualize the mifepristone-regulated gene expression process. In addition to
visualization, the luciferase marker also allows real-time quantification of gene
expression. Therefore, using the light-emitting proteins, the kinetics of induced gene
expression in the same group of cells can be monitored over a period of time.
A similar two-plasmid-mediated mifepristone-regulated gene expression system
(UAS/TAXI system) was constructed by Delort and Capecchi (1996). This
UAS/TAXI system is essentially the same as that of the “GeneSwitch” system except
for a few minor differences. Both inducible systems are based on two plasmids. The
chimeric transcriptional activator plasmid carries a hybrid transcriptional activator
construct encoding the fusion gene of the GAL4 DNA-binding domain, a truncated
hPR-LBD, and an HSV VP 16 activation domain linked to the CMV promoter. The
reporter plasmid carries a transcriptional activator-dependent marker gene fusion
construct using the GAL4 upstream response elements and a minimal synthetic
promoter (UAS) linked to the marker gene. One of the differences between the two
systems is that, in the chimeric transcriptional activator plasmid of the UAS/TAXI
system, the hPR-LBD has a 35 amino acid deletion in the carboxyl terminus.
However in the HPR-LBD of the “GeneSwitch” system there is a 42 amino acid
deletion in the carboxyl terminus. Another difference is that in the chimeric
transcriptional activator, the VP 16 acidic transactivation domain spans residues 415486 in the UAS/TAXI system, whereas in the “GeneSwitch,” the VP 16
transactivation domain spans residues 411-487. In the reporter plasmid constructs,
there are five GAL4 upstream response elements along with a minimal promoter
sequence from the Drosophila hsp70 gene in the UAS/TAXI system. However, there
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are four copies of the GAL4 upstream response elements linked to the adenovirus
major late E1B TATA sequence in the “GeneSwitch.” Also, in the UAS/TAXI
reporter plasmid, the GAL4 DNA binding domain spans residues 1-147 whereas in
the “GeneSwitch” system, it spans residues 1-94. Despite these differences, the
UAS/TAXI system has been demonstrated by Delort and Capecchi (1996) to be
functionally comparable to the “GeneSwitch” system in regulating gene expression in
the presence of mifepristone.
Mifepristone has been used clinically in conjunction with a low dose of
prostaglandin for termination of early pregnancy (Brogden et al. 1993). Mifepristone
treatment is also beneficial in treating unresectable, hormone-dependent tumors and
disorders of the female reproductive system that are resistant to conventional
chemotherapy and irradiation (Koide 1998). For example, mifepristone long-term
treatment of refractory Cushing’s syndrome caused by an ACTH-secreting pituitary
macroadenoma in extremely ill patients has been demonstrated (Chu et al. 2001). In
our studies, we use mifepristone, a progesterone analog, as an inducer drug to bind
and induce conformational changes in the mutant progesterone receptor, which is part
of the chimeric transcriptional activator. This allows the subsequent binding of the
chimeric activator to the synthetic promoter in the target gene construct and activates
gene expression.
The pharmacological kinetics and safety profile of mifepristone have been
carefully evaluated over the years. After ingestion, mifepristone is quickly absorbed
and has a half-life of 25 to 30 hours (Heikinheimo 1997). The initial metabolism of
mifepristone is catalyzed by cytochrome P450 enzyme CYP3A4 to yield

32

monodemethylated, didemethylated, and hydroxylated metabolites, which are in
similar concentrations to the original drug. The three metabolites and the original
drug are active as antagonists against endogenous progesterone. Long-term usage of
mifepristone is considered to be safe, as demonstrated in clinical trials (Glasier 1998).
No toxic effects were observed in humans even after long-term medical use in doses
up to 20 mg/kg (Handerson 1987). It was demonstrated that the serum concentration
of mifepristone after oral intake of 200 mg was estimated to be about 5 pM in adult
humans (Heikineheim et al. 1989). In our experiments, the optimal concentration of
mifepristone used was 250 nM, which corresponds to an oral dose of 10 mg. This is
significantly lower than the doses (600 - 800 mg) used for pregnancy termination.
Therefore, mifepristone can be applied safely in human subjects for regulating gene
expression.
Mammalian Cell Microencapsulation
Overview
Cell therapy utilizes implanted cells or tissues to secrete the deficient therapeutic
proteins to treat human diseases. The challenge facing allogenic or xenogenic cell
and tissue transplantation is immune rejection. To suppress such rejection, the
recipient host is subjected to daily immunosuppressant drug treatment. However, the
immunosuppression therapies are often accompanied by severe adverse effects, such
as nephrotoxicity (Olyaei et al. 1999; Olyaei et al. 2001). Although new drugs are
being developed to maximize the efficiency of immunosuppression and improve
patients’ quality of life (MacDonald 2001), the endogenous immunosuppressant
nature of the drug therapy inevitably puts patients at constant risk. To address this
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problem, a new approach to protect cells from immune rejection is encapsulation
using biocompatible polymers (Aebischer et al. 1991; Chang 1997; Wang 1998;
Rihova 2000; Uludag et al. 2000). These polymers physically isolate the cells from
immune attack. In addition to providing physical isolation, these polymers also
possess other features essential for successful cell therapy. For example, the pore size
of the polymers can be adjusted to allow for the passage of nutrients and therapeutic
molecules while excluding components of the immune system. The external surface
morphology and the mechanical strength of the polymers are also carefully designed
both to optimize the interaction between microcapsules and host, and to optimize the
durability of the capsules, respectively. There are three major systems of
encapsulation, including intravascular macrocapsules, extravascular macrocapsules,
and extravascular microcapsules (de Vos et al. 2002). In this study, we focus on
extravascular microcapsules, which possess many advantages over the first two types
of encapsulation. One of main advantages is the high surface to volume ratio. This
allows better diffusion of nutrients, therapeutic proteins, chemical stimulants, etc.,
into and out of the capsules.
The biocompatible materials for cell encapsulation can be divided into two major
groups: membrane materials and matrix materials. The AN69 hollow fiber
(polyacrylonitrite-sodium methallylsulfonate; Hospal, Meyzieu, France) is an
example of membrane material used to encapsulate cells and tissues. The AN69
copolymer was originally used as hemodialysis membrane (De Paepe and Ringoir
1982). It is highly biocompatible. The hollow fiber used for cell encapsulation is
typically 1 cm long and made of 8% AN69 polymer with an internal diameter of 100
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jam, a wall thickness of 140 jam, and a molecular weight cut-off of 80 kDa (Prevost et
al. 1995). After the loading of cells, the fiber is closed with surgical clips and ready
for implantation. So far, the immuno-isolation of hepatocytes (Bahadur et al. 1995;
Sarkis et al. 2001), of pancreatic islets (Honiger et al. 1994; Prevost et al. 1997), and
of transformed fibroblast cells (Serguera et al. 1999) using AN69 hollow fiber
encapsulation has been successfully demonstrated in animals and human patients.
These encapsulated and implanted cells and tissues are used to restore metabolic
function, thus paving the way for the further development of bioartificial organs for
clinical applications. Other examples of membrane materials that have been used for
cell microencapsulation include PAN/PVC membranes (Shoichet and Rein 1996),
polysulphone (PSU) polymers (Lembert et al. 2001; Petersen et al. 2001), and
polyurethane (Zondervan et al. 1992; Ward et al. 1993).
In addition to membrane materials that provide an outside capsule, matrix
materials are also used in cell encapsulations to provide the cells with an internal
environment that mimics the matrix structure of the extracellular space existing in
living organisms. Similar to the extracellular matrix, the matrix materials used in cell
encapsulation are designed to provide the cells with both physical support as well as
functional support for cell proliferation, polarity, secretion, etc. Calcium-crosslinked
alginate is one of the most widely used matrix materials for cell microencapsulation
(Peirone et al. 1998; Uludag et al. 2000). Chitosan (Zielinski and Aebischer 1994),
cellulose (Merten et al. 1991; Dautzenberg et al. 1999), and agarose (Iwata et al.
1992; Hayashi et al. 1996) are other examples of matrix materials used for
mammalian cell encapsulation.
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Cell and Tissue Encapsulation by Alginate/poly-L-lysine
Alginate is the most common material employed for microencapsulation. It is a
polysaccharide composed of negatively charged mannuronic and guluronic acids (Fig.
1.9), which can be gelatinized in polymerization buffer by linking guluronic acid
molecules together in the presence of divalent cations, such as Ca . Alginate can be
used either alone or in combination with poly-L-lysine (PLL). The positively charged
PLL interacts with the negatively charged mannuronic and guluronic acids on the
surface of gelatinized alginate to form a PLL membrane. The PLL membrane will
not only provide stability to the alginate beads but also control pore size by varying
the molecular weight and the concentration of PLL used, and also by varying the
incubation time and temperature of PLL solutions with alginate beads (King et al.
1987; Vandenbossche et al. 1991; Vandenbossche et al. 1993). Finally, the PLLcovered alginate beads are treated in alginate or other solutions containing negatively
charged ions to neutralize any excessive amount of positively charged lysine residues.
This external layer of alginate augments the strength and biocompatibility of the
alginate beads. In our studies, the alginate beads or alginate-microencapsulated cells
were all prepared using an INOTECH encapsulation apparatus (Fig. 1.10).
There are many advantages of using alginate/PLL microcapsules for cellular
encapsulation. The small alginate matrix is more reliable than a single large
membrane, which is more prone to be tom. The small alginate beads also have a
large surface area compared to a single large encapsulation membrane. The pore size
of the alginate/PLL beads can be adjusted to allow for free diffusion of nutrients,
wastes, and therapeutic proteins, while at the same time excluding immunoglobulins.
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Figure 1.9. The chemical structure of alginate. Alginate is a polysaccharide
sodium salt (Chaplin 2002).
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M: p-(l-4)-linked D-mannuronic acid
G: oc-(l-4)-linked L-guluronic acid
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Figure 1.10. The microencapsulation apparatus. (1) syringe pump; (2) syringe
(containing cells and alginate mixture); (3) nozzle; (4) vibration generator; (5)
alginate/cell droplets; (6) encapsulator cylinder; (7) bypass cup; (8) calcium
polymerization solution; (9) drainage valve; (10) alginate bead collection flask; (11)
stir rotor; (12) bypass cup rotor; (13) electrostatic charge generator; (14) electrode;
(15) waste passage. Please refer to Chapter 2 of the Materials and Methods section
for a detailed protocol of the operation of the encapsulator apparatus.
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Cells microencapsulated in spherical alginate/PLL beads can be implanted into
animals by direct injection into the peritoneal cavity or by subcutaneous implantation
with minimal invasive surgery. Further modifications of alginate/PLL encapsulation
techniques have shown promising results in reducing host immune response and
increasing the stability of the alginate/PLL capsules. A high rather than low
guluronic acid content of alginate is used to improve the stability of the bead to avoid
swelling and breakage after implantation (De Vos et al. 1996). Also, instead of saline
and citrate, Ca2+-free Krebs-Ringer bicarbonate buffer (KRBB) and ethylene glycolbis(p-aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA) are used as incubation
media to provide prolonged secretion of therapeutic proteins from encapsulated cells
and tissues (Fritschy et al. 1991). Furthermore, instead of Ca2+, barium (Ba2+)
(Schrezenmeir et al. 1993; Petruzzo et al. 1997; Duvivier-Kali et al. 2001) and
strontium (Sr2+) (Thu et al. 1996; Wideroe and Danielsen 2001) have been used as the
divalent cations for alginate polymerization. Unlike Ca2+, which can only bind to
guluronic acids, Ba2+ can bind to both guluronic and mannuronic acids, and therefore
provides a high level of crosslinking and increased durability. Strontium alginate also
showed a considerably higher chemical stability than Ca -alginate for long-term
usage in vivo (Wideroe and Danielsen 2001). And lastly, instead of the traditional
spherical beads, non-homogeneous planar alginate beads with a higher concentration
of alginate in the periphery than in the center core have been produced (Thu et al.
1996a; Thu et al. 1996b). The non-homogeneous beads have great stability and allow
the modulation of bead permeability in the absence of PLL. In summary, these
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material and procedural modifications will further facilitate the application of alginate
in cellular encapsulation and implantation.
Lim and Sun (1980) were the first to employ alginate-based encapsulated islets to
reverse insulin-dependent diabetes in rats. Subsequently, promising results in treating
type I diabetes were obtained in large animals (Soon-Shiong et al. 1992; Soon-Shiong
et al. 1993; Calafiore et al. 1999; Lanza et al. 1999) and in human patients (SoonShiong et al. 1994). In addition to treating diabetes, many other metabolic diseases
could be treated using alginate-encapsulated cell therapy. For example, hormone
deficiency diseases were treated in animals using encapsulated endocrine cells (Sun et
al. 1987). Secretion of functional parathyroid hormones (Gaumann et al. 2001),
human growth hormone (hGH) (Chang 1997; Peirone et al. 1998a; Ross et al. 1999;
Stockley et al. 2000), and testosterone (Machluf et al. 200) by encapsulated cells has
been demonstrated in cultures and in animal models, which could be applied
clinically in treating human diseases. In addition to hormones, the delivery of other
recombinant gene products, such as lysosomal enzymes (Ross et al. 2000), adenosine
deaminase (Hughes et al. 1994), human coagulation factor IX (Liu et al. 1993;
Hortelano et al. 1996; Garcia-Martin et al. 2002), inducible nitric oxide synthase
(iNOS) (Xu et al. 2002), endothelial cell growth factor (Ko et al. 1995), and
endostatin (Read et al. 2001), from alginate-encapsulated cells appears to be a
promising strategy for the potential treatment of human diseases.
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Renilla Luciferase (Rue) and Aequorea GFP as in vivo Markers
Rue
The sea pansy Renilla reniformis is a bioluminescent soft coral living in shallow
water off the coast of North America. Upon mechanical stimulation, the sea pansy
displays blue-green bioluminescence, which is the result of a photon-emitting
reaction catalyzed by Renilla luciferase (Rue). Rue is one of the members of the
luciferase family of proteins isolated from a large variety of organisms (Hastings
1996; Greer and Szalay 2002). The rue cDNA, cloned and sequenced by Lorenz et
al. (1991), is 1196 base pairs in length, and encodes a 314 amino acid glycoprotein of
34 kDa. Rue catalyzes the oxidation of coelenterazine, the luciferin of Renilla
reniformis (Fig. 1.11). The coelenterazine substrate consists of an imidazolopyrazine
structure {2-(p-hydroxybenzyl)-6-(p-hydroxyphenyl)-8-benzylimidazo [ 1,2a]pyrazin-3-(7H)-one}, which emits blue light with a peak at 480 nm when oxidized
by Rue (Hori et al. 1973; Matthews et al. 1977). Unlike firefly luciferase (DeLuca
and McElroy 1974; de Wet et al, 1987), Rue does not require cofactors or ATP for
activity. It should be noted that the in vitro Rue assay is sensitive to the ionic strength
of the buffer (Ward and Cormier 1978), but relatively insensitive to variation in pH
and temperature.
Recombinant Rue was first expressed in E. coli (Lorenz et al. 1991), and was
determined to have identical characteristics to native Rue based on Western blot and
luminescence emission spectra analyses. Although native Rue is a glycoprotein,
glycosylation is not required for the enzymatic activity of Rue. Recombinant Rue
expressed in E. coli strains, which lack a glycosylating enzyme (Littman et al. 1985),
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Figure 1.11. Bioluminescence reaction catalyzed by Renilla luciferase. In the
presence of molecular oxygen, coelenterazine is oxidized to coelenteramide, with a
concomitant release of carbon dioxide and blue light (peak at 480 nm).
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is functional in catalyzed luminescent light-emitting reactions. Subsequently,
functional Rue was successfully expressed in Candida albicans (Srikantha et al.
1996), in plants (Mayerhofer et al. 1995), in mammalian cells (Lorenz et al. 1996;
Liu et al. 1997; Liu et al. 2000; Yu et al. 2001; Timiryasova et al. 2001), embryos
(Wang et al. 1996), and adult animals (Yu et al. 2001; Bhaumik and Gambhir 2002).
Rue as a Biomarker
Compared to conventional molecular markers, such as p-galactosidase-based
staining or fluorescent dye, there are many advantages associated with Rue as a
biomarker. First, Rue is a biomarker that can be monitored in real time. The
expression of Rue is indirectly measured by assaying the luciferase enzymatic
activity. Since the luciferase assay is based on light emission, no invasive
procedures, such as staining, are required for detection. Due to the availability of
highly sensitive photon counting instruments, Rue can be assayed with a higher
sensitivity than GFP fluorescence. Also, the latter often suffers from strong
interference by intrinsic sample fluorescence. Second, luciferase gene expression can
be easily quantified based on photon emissions (Liu et al 1997; Liu et al. 2000).
Quantification of GFP expression, on the other hand, is difficult. Third, no direct
toxicity of Rue has been observed in either cell culture studies (Lorenz et al. 1996) or
in animal studies (Bhaumik and Gambhir 2002). However, it has been suggested that
overexpression of GFP can cause apoptosis in certain cell cultures (Liu et al. 1999a).
One of the limitations of using Rue as a biomarker is that the Ruc-catalyzed lightemitting oxidation reaction is dependent on the presence of molecular oxygen.
Therefore, when the oxygen supply is limited, such as in poorly vascularized tissues,
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luciferase activity is also restricted. Another limitation associated with Rue is the
need of the substrate coelenterazine for light emission. Efficient delivery of
coelenterazine could be problematic in animal studies (Bhaumik and Gambhir 2002).
In addition, since the coelenterazine substrate is generally prepared in ethanol or
methanol, injection of an excessive volume is toxic to the animals.
Luciferase Imaging Techniques
Photon emission from Ruc-catalyzed oxidation of coelenterazine can be
monitored using any of the following instruments or similar models: (1) a Turner
Designs TD 20e luminometer (Turner Designs, Sunnyvale, CA), (2) a SPEX
FluoroMax spectrofluorometer (Instruments S.A. Inc., Edison, NJ), (3) a Hamamatsu
ARGUS 100 low light imager (Hamamatsu, Japan), or (4) an EG&G Nightowl low
light imager (Berthold Technologies, GmbH and Co. KG, Bad Wildbad, Germany).
The TD 20e luminometer has sensitivity and versatility specifically suited for use
with Renilla and firefly luciferases. To detect luminescence light emission using the
luminometer, samples suspended in luciferase assay buffer are transferred into
scintillation vials. Coelenterazine is either injected into the vials by a Hamilton
syringe or by pipetting. It is important to determine the linear range of the
luminometer since high intensity light results in signal saturation. Light intensity is
proportional to luciferase concentration in the range between 10'16 M (=10 pg/L) and
o

10' M (=1 mg/L). A standard curve of relative light units vs. luciferase concentration
can be plotted using serial dilutions of purified Renilla luciferase (Sigma, St. Louis,
MO) in luciferase assay buffer. A supplement of 1 mg/ml BSA is added to the
solution to prevent luciferase from attaching to the container surface. The
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luminescence intensity (reported in relative light units) can be converted into photons
/TO

per second by calibrating the luminometer relative to a radioactive Ni light standard,
which emits light in the 460-480 nm wavelength range (O’Kane and Lee 1990). The
Rue assay using a spectrofluorometer is carried out in quartz cuvettes. Immediately
after the addition of coelenterazine, samples are scanned across a broad wavelength
centered on 480 nm. The results of photon emission can be reported as counts per
second. Data can be collected using software provided by the system (DataMax for
Windows™). All of the data can be exported as ASCII XY data and processed using
the SigmaPlot for Windows version 4.0 software or using Microsoft Excel 2000 for
Windows. To detect luminescence light emission using low light imagers (by
Argus 100 or by Nightowl), samples are prepared in titer plates. After the addition of
coelenterazine, the titer plate is put in the dark box of the low light imager. Photon
collection is performed for a specified period of time to obtain a low light image.
Then, a photographic image is taken with either the low light imager or a Fuji
Finepix4900 digital camera. The low light image is superimposed over the
photographic image using Adobe Photoshop 5.0 software to record the location of
luminescent activity. The luminescence emission can also be quantified by the low
light imager and reported as total counts of photon emission for a specified duration
of time in a designated area.
Aequorea GFP
The cDNA of GFP was cloned from the jellyfish^egworaa victoria (Prasher et
al., 1992). At pH 7.0, excitation of the wild type GFP by light with a wavelength of
398 nm induces emission of bright green fluorescence with a peak at 508 nm (Ward
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and Bokman, 1982). Since the energy needed to generate fluorescence can be
acquired through exogenous light absorption, no endogenous or exogenous substrate
is needed. Therefore, upon exposure to excitation, its presence and movement can be
visualized externally based on fluorescence in real time in live cells and animals,
without the need of fixation or staining procedures. A native GFP molecule is
relatively stable and can remain functional for up to 24 hours in cells. It is stable
upon heating up to 65 °C as well as after treatment with 4% paraformaldehyde (Cubitt
et al., 1995). No mammalian homologue of GFP exists, thus there is no endogenous
interference with introduced GFP fluorescence. The unique combination of features
present in this small protein of approximately 200 amino acid residues makes it an
ideal candidate for use as a biomarker.
To enhance fluorescence and extend or decrease the stability of the wild-type
protein at higher temperatures, a number of laboratories have modified the native
GFP structure (Heim et al., 1994; Delagrave et al., 1995; Ehrig et al., 1995; Heim et
al., 1995; Cormack et al., 1996; Crameri et al., 1996; Heim and Tsien, 1996; Yang et
al., 1996; Zhang et al., 1996; Kimata et al., 1997; Li et al., 1998; Yang et al., 1998;
Stauber et al., 1998; Ito et al., 1999). The coding sequences for mutants have also
been designed with codon changes to optimize expression in the mammalian system
(Zolotukhin et al., 1996). Mutants of GFP have been generated with 20 to 35 fold
higher intensity than wild type GFP (Cormack et al., 1996). Enhanced GFP (EGFP) is
a mutant form of GFP that offers an equal or higher sensitivity of expression
detection than that of p-galactosidase staining in cell cultures (Zhang et al., 1996).
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To simultaneously monitor the fate of more than one protein in the same cell,
GFP color variants emitting light at different wavelengths have been constructed and
applied successfully in many studies (Siemering et al, 1996; Zemicka-Goetz et al,
1997; Ellenberg et al., 1999; Gibbs and Schmale, 2000; Hadjantonakis and Nagy,
2001). GFP variants with increased stability are not always desirable as reporter
proteins. In gene expression studies to monitor target transcription or translation, a
reporter protein with quick turnover is essential. To achieve this goal, Li et al. (1998)
constructed a destabilized chimeric EGFP protein by fusing the degradation domain
of mouse ornithine decarboxylase to the C terminus of EGFP, resulting in a
shortening of the EGFP half-life to about 2 hours. Other GFP variants with rapid
degradability have also been described (Chiang et al., 2001). These GFPs with
shorter half-lives are excellent markers for real-time gene induction studies.
Another advantage of GFP as an in vivo marker protein is that individual cells or
subpopulations can be easily monitored, due to its strong fluorescent emission. For
example, the contraction of individual cardiomyocytes can be visualized based on
GFP fluorescence in live embryos (Fleischmann et al., 1998). Therefore, GFPtransformed cells can be traced spatially and temporally in a nondestructive fashion
throughout the entire experiment. Expression of GFP under ubiquitous promoters has
been observed in a variety of tissues, without display of cell or tissue preference.
Furthermore, GFP labeled cells can be isolated from cell cultures or animals by
fluorescence activated cell sorting (FACS) and used for in vitro studies of isolated
cell types. Although high levels of GFP expression may be toxic (Hanazono et al.,
1997), no abnormalities associated with organismal development have been linked to
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modest GFP expression in animals transformed with a gfp expression construct
(Okabe et al., 1997; Pratt et al., 2000; Chan et al., 2001).
Application ofAequorea GFP as a Biomarker
Labeling cells with GFP.
Classical cell labeling studies have utilized techniques including chimeric tissue
transplants (Beresford, 1983; Ambler et al., 2001), intracellular injection of
carbocyanine dyes (Di I, DiA or DiO) and intracellular injection of fluorescent dyes
(Seleck and Stem, 1991; Clarke and Tickle, 1999). Mapping dynamic processes is
limited in transformed cells and in chimeric transplants since visualization based on
histological staining is not possible in the living cells or organisms. Similarly, the
carbocyanine dyes generally require tissue processing for visualization. Fluorescent
dyes, on the other hand, can be monitored in living cells and organisms. However,
diffusion of the injected dye during cell growth limits its usefulness as a long-term
marker. In contrast, cells can be transiently and stably transformed using GFP
expression constmcts, and subsequent GFP expression allows the monitoring of cell
growth and proliferation.
There are several ways to label cells with GFP. Individual cells or cell groups can
be injected with purified cRNAs. This method allows the cytoplasmic translation and
the generation of GFP. However, the cRNA is rapidly degraded, leaving only the
stable protein to be passed on to subsequent progeny cells (Peters et al. 1995).
Another method of labeling cells with GFP is to deliver GFP-encoding gene
constmcts intracellularly by transient transformation, thus allowing passage of the
transgene to progeny cells. Transgene delivery can be achieved by a variety of

51

methods including direct DNA injection, electroporation, or viral transduction.
Promoters used for this purpose can be ubiquitous, such as the chicken (3-actin
promoter, or tissue-specific. Examples of promoters used for ubiquitous GFP
expression include the Drosophila polyubiquitin promoter (Davis et al., 1995), the
cytomegalovirus (CMV) promoter (Takeuchi et al., 1999; Damjanovski et al., 2001;
Nutt et al., 2001), the Xenopus heat shock protein 70 (Xhsp70) promoter (Wheeler et
al., 2000), \h.Q Xenopus borealis cytoskeletal actin (CSK) promoter (Kroll and
Amaya, 1996), the ROSA26 (R26) promoter (Kisseberth et al., 1999), and the P-actin
promoters from carp (Gibbs and Schmale, 2000), from medaka (Hamada et al., 1998),
and from chicken (Ikawa et al., 1995b; Okabe et al., 1997; Shimada et al., 1999;
Okada et al., 1999). Examples of promoters used for tissue-specific GFP expression
include the muscle creatine kinase (MCK) promoter (Ju et al., 1999), the astrocytespecific glial fibrillary acidic protein (GFAP) promoter (Zhuo et al., 1997), the
murine type II collagen (co/2) promoter in chondrocytes (Grant et al., 2000), and the
L7 promoter in Purkinje cells (Tomomura et al., 2001). An alternative method for
targeting specific tissues without using tissue-specific promoters is to implant stably
transformed cells of that tissue type or transformed totipotent cells. For instance,
Amhold et al. (2000) established a D3-derived embryonic stem cell line transformed
with a chicken p-actin promoter-g/p construct. After the implantation of these cells
into the rat striatum, the migration and differentiation of these GFP-labeled
embryonic stem cells were successfully monitored. The authors further described a
subpopulation of these GFP-labeled cells that differentiated into neurons positive for
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the neuronal marker Thy-1, and also into astrocytes positive for glial fibrillary acidic
proteins.
Analysis of promoter activation using promoter-g/b fusion constructs.
It has been confirmed repeatedly that the specificity of transgene expression from
tissue-specific promoters correlates with the tissue in transformed organisms (Kroll
and Amaya, 1996; Fleischmann et al., 1998; Anderson et al, 1999; Fukushige et al.,
1999; Offield et al., 2000; Koster and Fraser, 2001). Therefore, linking the gfp
cDNA to DNA elements with promoter activity, followed by analysis of the in vivo
location of transgene expression, constitutes a valid approach to obtaining tissuespecific function of regulatory sequences. The general strategy is to isolate DNA
fragments of the 5’ and 3’ flanking regions of the gene of interest. After sequential
resection of these flanking sequences, each fragment is linked with a gfp cDNA or by
fusion between the gene of interest and a gfp cDNA. The resulting constructs are
injected into early stage embryos (e.g. one-cell stage, or individual blastomeres) to
analyze GFP expression patterns. Using this method, studies have demonstrated that
GFP can be used to help identify regulatory regions that provide spatial and temporal
control of gene expression (Long et al., 1997; Krempen et al., 1999; Meng et al.,
1999; Drivenes et al., 2000; Kusakabe and Suzuki, 2000; Ryffel and Lingott, 2000;
Anyanful et al., 2001; Liu and Green, 2001; Martin et al., 2001; Ryu et al., 2001).
Furthermore, reporter gene systems have been designed to allow inducible GFP
expression from promoters that can be activated by exogenous inducers. For
example, Mattingly et al. (2001) demonstrated that the environmental toxin 2,3,7,8tetrachlorodibenzo-p-dioxin (TCDD) induces the expression of gfp under the control
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of the aryl hydrocarbon receptor (AhR) promoter. This finding shows that the
promoter-g/p fusion system may become a powerful tool to study promoter activation
and transcriptional regulation (Amone et al., 1997).
Use of target protein-GFP fusions to study protein function during embryonic
development.
Mutational analysis and protein over-expression have been frequently used to
study how individual proteins affect cell function. However, one of the main
problems of using conventional staining or dye methods for these studies is that
experimental observations are made based on information obtained from cells and
organisms at different time points. Therefore, interpretation of such results is difficult
since observations were made on different cells or organisms. Moreover, incorrect
conclusions may be drawn unless a sufficient number of specimens have been
examined. To overcome these difficulties, new techniques need to be developed so
that cellular events can be studied in real-time. This can be accomplished by fusing a
gfp cDNA to the gene of interest. Using GFP as a live marker, information can be
obtained on cellular, subcellular, and tissue localization of the protein of interest
(Marshall et al. 1995; Htun et al. 1996; Cormack 1998; Phillips 2001), on onset and
duration of protein expression at a certain stage of cell proliferation and
differentiation (Godwin et al. 1998; Friedman et al. 2000; Mateus and Avery 2000),
on agonist induced protein translocation and aggregation (Fejes-Toth et al. 1998; Zhu
et al. 1998; Liu et al. 1999b) and on many other signal transduction events (Kallal and
Benovic 2000; Zaccolo and Pozzan 2000; Chiesa et al. 2001; Kabuta et al. 2002; Sato
et al. 2002).
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Fluorescence-based GFP detection in living cells and organisms may present
some experimental difficulties. A few words of caution: Most of the gfp fusion
constructs lack introns and 5 ’ and/or 3 ’ untranslated flanking regions of the target
gene, which may contain the potential regulatory sequences (Inoue and Thomas,
2000). Therefore, the GFP reporter protein expression patterns may not represent
those of endogenous proteins. In addition, the synthesis and maturation of GFP
requires at least two hours. Due to this time lag, it is difficult to determine the precise
time of transcriptional activation in short time intervals during dynamic cell growth
(Davis et ai, 1995; Timmons et al., 1997; Hazelrigg et al., 1998; Fay et al., 1999;
Tanaka et al., 2001). Furthermore, many GFP variants, such as EGFP, are very stable
in vivo. GFP fluorescence, which may be the result of the accumulation of current
and previous episodes of GFP expression, may not accurately reflect the
transcriptional activation of an endogenous target gene at a given point in time
(Amone et al., 1997). Currently, due to the possibility of “transgenic mosaicism”
(Palmiter et al., 1984; Chan et al., 1999), one cannot rule out that tissue-specific GFP
expression is the result of uneven distribution and expression of a transgene in
different cells of the organism. Cell type specificity of an unknown promoter can be
verified only when a statistically significant number of transiently transformed
organisms have been analyzed.
GFP Imaging Techniques
GFP expression in organisms and single living cells can be visualized by a
conventional wide-field fluorescence microscope with GFP filter sets (e.g. the Nikon
Endow GFP Longpass Emission (FGP(R)-LP) filter combinations). However, this
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method of imaging can be complemented with laser scanning confocal microscopy
(LSCM) due to LSCM’s out-of-focus correction and optical sectioning capabilities
for three-dimentional image reconstruction. More recently, two-photon laser
scanning microscopy (TPLSM) has been developed (Denk et al., 1990) to increase
tissue penetration ability and decrease photobleaching, photodamage, and
auto fluorescence that cannot be resolved using LSCM. Periasamy et al. (1999) have
compared three imaging techniques (TPLSM, LSCM, and conventional widefield
digital deconvolution microscopy (DDM)) for studying cells in deep tissues. TPLSM
shows the most promising deep tissue imaging (>30pm) capability that allows highresolution time-lapse microscopy. The advantages and disadvantages of some of the
GFP imaging techniques are summarized in Table 1.

Renilla Luciferase - Aequorea GFP Fusion Protein
The Renilla luciferase

gfp fusion gene (ruc-gfp) was constructed by

Wang et al. (2001). There is a 15-base-pair linker bridging the Renilla luciferase
cDNA with the cDNA of GFP in frame. The fusion gene was linked to either a CMV
promoter or a chicken (3-actin promoter for expression in mammalian cells. Western
blot analysis confirmed the expression of the fusion protein. A transformed Chinese
hamster ovary cell line stably expressing the Ruc-GFP fusion protein was also
established. Fluorescence in situ hybridization (FISH) analysis located the ruc-gfp
fusion gene on a single chromosomal locus. The recombinant fusion protein was
demonstrated to be functional. Luminescence resonance energy transfer (LRET) was
established. Fluorescence in situ hybridization (FISH) analysis located the ruc-gfp
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Table 1. GFP imaging techniques
TECHNIQUES
Wide-field epifluorescence
microscopy (FM)

DESCRIPTION
- conventional
wide-field epifluorescence
excitation

ADVANTAGES
- easy and fast
fluorescence image
aquisition
- inexpensive system

Digital imaging
microscopy (DIM)

- wide-field
fluorescence
microscopy
- using
sequentially
focused images
and computational
algorithms to
reconstruct highresolution 3-D
images
- high-intensity
short wavelength
excitation of
fluorescence at a
given focal plane

- weaker illumination
requirement than
laser scanning
confocal microscopy,
low photobleaching
and photodamage
- fast image
acquisition
- high spatial
resolution 3-D
images
- optical sectioning
ability through thick
tissues for 3-D image
reconstruction
- can be configured to
perform dual-color
imaging with GFP
variants
- Although cellular
photodamage is
likely, frequent
exposure of
organisms to low
laser power confocal
imaging generally
does not interfere
with organismal
development.
- high sensitivity with
high signal/noise
ratio due to low
background
fluorescence
- low photo
bleaching or
phototoxicity
- almost no excitation
of cells outside of
focal plane
- great depth of tissue
penetration
- time-lapse kinetic
studies
- 3-D and 4-D
(repetitive 3-D)
image reconstruction

Single-photon
laser scanning
confocal
fluorescence
microscopy
(LSCM)

Two-photon or
multiple-photon
laser scanning
fluorescence
microscopy

- use of a pulsed
long excitation
wavelength, such
as an infrared (IR)
laser beam, to
excite fluorescence
at a focal plane
- simultaneous
excitation of the
fluorescence
molecule by two
photons

57

DISADVANTAGES
- out-of-focus
background light
interferes with
imaging
- poor tissue
penetration ability,
not capable of optical
sectioning, i.e., 2-D
images

REFERENCES
Green et al.2000;
Kubitscheck et al.
2000; Falk and
Lauf2001

Rizzuto et al.
1998; Howell et al.
2000; Yang et al.
2001

- high photobleaching
and phototoxicity to
cells on the focal
plane as well as to
the cells above and
below the focal plane

Zemicka-Goetz et
al. 1997; Cooper et
al. 1999; Dailey et
al. 1999; Ellenberg
et al. 1999; Kulesa
and Fraser 1999;
Robb and Wylie
1999; Webb 1999;
Kiehart et al. 2000;
Paddock 2000;
Gautier et al. 2001;
Reynaud et al.
2001

- expensive system

Potter et al. 1996;
Periasamy et al.
1999; Pamass et al.
2000; Huang et al.
2001; Lansford et
al. 2001

fusion gene on a single chromosomal locus. The recombinant fusion protein was
demonstrated to be functional. Luminescence resonance energy transfer (LRET) was
observed in the fusion protein (Wang et al. 2001). In the LRET studies, spectroscopic
analysis of cells expressing the Ruc-GFP fusion protein in the presence of
coelenterazine substrate resulted in two emission peaks at 471 nm and 503 nm, which
correspond to the emission maxima of Rue and GFP respectively. The GFP peak was
the result of intramolecular LRET from Rue to GFP in the absence of any exogenous
excitation light. In addition to ruc-gfp, a second fusion gene, namely gfp-ruc, has
also been constructed and expressed in mammalian cells (Wang et al., unpublished
data). In this second fusion, the cDNA of GFP was fused to the 5’ end of the Renilla
luciferase cDNA with a linker of 21 base pairs in between. Interestingly, GFP-Ruc
exhibited better LRET than Ruc-GFP, by showing a stronger emission peak at 503
nm in the presence of coelenterazine. It was reasoned that since the carboxyl
terminus of GFP is more physically and functionally flexible than the amino terminus
(Ormo et al 1996; Youvan and Michel 1996; Li et al. 1997; Wachter et al. 1997), the
fusion of Rue to the carboxyl terminus of GFP allows a greater probability of
intramolecular proximity between the Rue and GFP domains, and hence a more
efficient LRET.
Effect of the GFP Tag on the Structure and Function of the Protein Fusion Partner
Most proteins when fused to GFP exhibit no interference with protein folding and
function during cell growth and organism development (Okada et al., 1999). Mouse
embryos and embryos of C. elegans, expressing GFP fusion proteins, developed into
normal adults. It has also been shown that target protein-GFP fusion products can
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rescue the fusion partner null phenotype (Wang and Hazelrigg, 1994; Endow and
Komma, 1996; Fukushige et al., 1999; Jiang and Sternberg, 1999; Chen et al., 2000;
Friedman et al., 2000; Du and Chalfie, 2001; Glenn and Searles, 2001). For example,
Ezrin::GFPc (GFP fused to the carboxy terminus of full-length Ezrin) has been shown
to behave like the endogenous protein in mouse embryos, accumulating at the apical
pole of the blastomeres during compaction and persisting at this localization during
the later stages in outer layer cells (Dard et al., 2001). In another example, similar to
endogenous decapentaplegic (Dpp), the Dpp::GFPc fusion protein can form an active
gradient in the wing imaginal disc and restore normal wing patterning and
development in mutant dpp Drosophila (Teleman and Cohen, 2000). GFP fusion
proteins can be generated by attaching GFP as a tag to either the N-terminus or the Cterminus of a given target protein, by inserting the gfp cDNA within the target protein
encoding sequence (Siegel and Isacoff, 1997; Biondi et al., 1998; Yamao et al., 1999,
Wang et al. 2001), or by inserting target protein encoding sequences into the GFP
encoding DNA fragment (Baird et al., 1999). Analysis of the literature revealed that
most of the fusion proteins have the target proteins connected to the N terminus of
GFP without using linker sequences. It has been suggested that a linker peptide is
helpful when the C terminus of GFP is fused to the target protein (Cubitt et al., 1995).
In the examples of Ezrin: :GFPc and Dpp::GFPc fusion proteins, the presence of GFP
at the carboxyl-terminal end of the target proteins did not interfere with target protein
function and localization (Teleman and Cohen, 2000; Dard et al., 2001).
Although the GFP fusion proteins usually exhibit normal GFP and target protein
functions, the 27 kDa GFP tag, a relatively large moiety, may interfere with the native
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structure and function of the target protein. It has been shown that cells expressing
GFP fusion proteins behave somewhat differently than those cells expressing the
target protein alone (Mao et al., 2000). For example, gap junction formation is
crucial in normal neuronal differentiation, trophoblast differentiation, and in
coordinating cardiac development. In the gap junction experiments, although
connexin 43-GFP fusion proteins were shown to form functional channels, a lower
level of electrical coupling was observed in cells expressing connexin 43-GFP than in
cells expressing connexin 43 alone (Mao et al. 2000). The C terminus of connexin 43
is thought to act as a gating particle (Bruzzone et al. 1996), which may explain why
tagging GFP to this portion of the protein may interfere with connexin function (Mao
et al. 2000). In addition, the connexin 43-GFP transformed cells were more easily
pulled off the coverslip by the microelectrodes than connexin 43 cells indicating that
they may be less adherent to neighboring cells (Mao et al. 2000). In another study,
the human slow poke (hSlo) K+ channel protein was tagged with GFP at the Nterminus of its a-subunit and was expressed transiently in human embryonic kidney
293 cells (Meyer and Fromherz, 1999). Whole cell patch-clamp data indicated the
fusion protein formed functional voltage-gated channels. However, the additional
presence of the GFP tag lowered the threshold of Ca2+ mediated K+ channel
activation, thus indicating a lowering of the voltage threshold of gating. In a third
example, the expression of the fusion form of the y-aminobutyric acid (GABA) pi
receptor with GFP took longer than p 1 receptor alone in Xenopus oocytes (MartinezTorres and Miledi, 2001). Also, cells with pi receptor::GFP fusion proteins exhibited
a smaller GABA current than those with wild type p 1 receptor. The authors reasoned
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that this difference was due to the decreased assembly of functional p 1 receptors on
the cell surface when fused with GFP. When gfp was inserted into the middle of the
gene encoding the cAMP-dependent protein kinase regulatory subunit, not
surprisingly, a moderate disturbance of fusion protein folding was observed as
indicated by changes of the cAMP binding capacity (Biondi et al., 1998). It was also
found that cells over-expressing GFP are more prone to undergo apoptosis (Liu et al.
1999a). An over-expression of GFP was found to interfere with normal embryonic
development (Sussman 2001). Therefore, it is important to be cognizant of these
negative effects of GFP when interpreting data obtained by using target protein-GFP
fusions.
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CHAPTER TWO
MATERIALS AND METHODS
Plasmid Vectors
“GeneSwitch ” Plasmid Vectors
The construction of reporter plasmid pl7x4-TATA-rwc-g/p has been described
previously (Yu et al. 2001). The chimeric transcriptional activator plasmid (PAP
CMV-GL914VPc’SV) was a gift from Dr. Y. Wang (Department of Cell Biology,
Baylor College of Medicine, Houston, TX). We used these two plasmids to express
the ruc-gfp fusion gene under the induction of mifepristone.
Sequencing vector, pBluescript KS(+)II (Strategene, La Jolla, CA)
This plasmid vector is a double-stranded DNA of 2.9 kb. It is a derivative of the
pUC plasmid (Vieira and Messing 1982; Norrander et al. 1983; Yanisch-Perron et al.
1985), which has a prokaryotic FI replication origin. We used this vector to clone
various cDNAs into the multiple cloning sites for DNA sequencing.
pLEIN (Clontech, Palo Alto, CA)
This plasmid vector is a retroviral shuttle vector carrying an egfp expression
cassette under the control of the constitutive 5 ’ LTR promoter. It is derived from the
pLXIN retrovirus shuttle vector, a double stranded DNA of 6.1 kb, which contains
multiple cloning sites downstream of the 5’ LTR promoter for expression of the geneof-interest. Following the multiple cloning sites is an internal ribosomal entry site
(IRES) and a neomycin resistance gene. The 5’ LTR promoter controls the
expression of both the gene-of-interest and the neomycin resistance gene. In addition
to the neomycin resistance gene for selection of stable transformants in eukaryotic
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cells, this vector also carries an ampicillin resistance gene for selection in bacteria.
We used this plasmid to produce retrovirus, which carries the ruc-gfp fusion gene
expression cassette.
pcDNA 3.1 (Invitrogen, Carlsbad, CA)
This plasmid vector is a double-stranded DNA of 5.4 kb. The pcDNA 3.1 is
designed for high-level, constitutive expression of a gene-of-interest under the control
of the cytomegalovirus (CMV) enhancer-promoter in mammalian cells. It has large
multiple cloning sites downstream of the CMV enhancer-promoter, followed by a
bovine growth hormone (BGH) polyadenylation signal and a transcription
termination sequence. The pcDNA 3.1 has a SV40 origin for episomal replication in
cell lines that express the large T antigen, such as COS1 and COS7 cells. It also has a
pUC origin for replication in bacteria. The pcDNA 3.1 carries the neomycin
resistance gene for selection of stable transformants in mammalian cells and the
ampicillin resistance gene for selection in bacteria. We used this plasmid to
constitutively express the Ruc-GFP fusion protein in mammalian cells.
pCX (Ikawa et al. 1995)
This plasmid vector is a double-stranded DNA of 3.8 kb. It carries a CMV
immediate early enhancer and a chicken p-actin promoter for high-level constitutive
expression of a gene-of-interest in mammalian cells. A single EcoR\ cloning site is
located downstream of the chicken P-actin promoter for cloning a gene-of-interest.
Downstream of the EcoR\ site is the polyadenylation signal and transcriptional
termination sequences from the rabbit P-globin gene. The pCX plasmid vector has
replication origins for both bacteria and mammalian cells (SV40 ori). The plasmid
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carries the ampicillin resistance gene for selection of stable transformants in bacteria.
There is no drug-resistance marker in this plasmid for selecting stable transformants
in mammalian cells.
cDNA Sequences
The Renilla Luciferase cDNA (Genbank Access Number M63501)
The rue cDNA, cloned and sequenced by Lorenz et al. (1991), is 1196 base pairs
in length. It encodes a 314 amino acid glycoprotein of 34 kDa.
The “humanized” Aequorea GFP cDNA (Genbank access number U50963)
(Zolotukhin et al. 1996)
“Humanized” GFP is synthesized with optimized codon usage for expression in
mammalian cells. It encodes a polypeptide of 238 amino acids with a calculated
molecular weight of 26.9 kDa.
The Renilla Luciferase-Aequorea GFP Fusion Gene (Wang et al. 2001)
The coding sequence of rue is fused in frame to the 5 ’ terminus of the gfp coding
sequence. There is a short 15 bp linker between the two genes.
Bacterial Strains
E. coliy DH5a [FVendAl lisdRl? (rkmk ) supE44 thi-1 recAl gyrA (NaT) relAl
A(laclZYA argF)U169 deoR(q) 80dlacA(lacZ)M15)J
This strain was used as a host for all plasmid construction and amplification.
DH5a was cultured at 37 °C in LB medium with continuous shaking at 200 rpm or on
LB agar plates in an incubator.
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Mammalian Cell Lines
The COS-7 Cell Line (ATCC: CRL-1651)
COS-7 is a cell line derived from African green monkey kidney tissue. It was
transformed by the SV40 virus (Gluzman 1981). COS cells form a fast growing
monolayer, which can be cultured in DMEM medium (Cellgro®, Mediatech,
Herndon, VA) supplemented with 2 mM glutamine, 10% FBS, and penicillin (100
lU/ml) / streptomycin (100 pg/m) antibiotics, or in supplemented RPMI-1640
medium (Cellgro®, Mediatech, Herndon, VA). COS cells can be easily transformed
with plasmid DNAs using many commercially available methods, including calcium
phosphate precipitation (Promega, Madison, WI), FuGENE-6 (Roche Diagnostics,
Indianapolis, IN), Lipofectamine (Life Technologies, Gaithersburg, MD), and
SuperFect (Qiagen, Valencia, CA).
The HT1080 Cell Line (ATCC: CRL-7951)
HT1080 is a human fibrosarcoma cell line derived from human bone. HT1080
cells form a fast growing monolayer, which can be propagated in supplemented
DMEM medium or in MCDB302 medium (Sigma-Aldrich, St. Louis, MO). Plasmid
transformation of HT1080 cells has been successfully performed using calcium
phosphate precipitation, or the FuGENE-6 and Lipofectamine kits.
Molecular Cloning Techniques Used in Plasmid Construction
In modem molecular and cellular biology research, transgenes are routinely
introduced into prokaryotic and eukaryotic hosts using plasmid vectors as carriers.
There are four steps involved in recombinant plasmid preparation: transgene and
linearized plasmid DNA preparation, DNA ligation, bacterial transformation, and
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positive clone identification. To prepare the transgene-containing fragment and the
linearized plasmid, both the transgene DNA and the plasmid DNA are digested with
restriction enzymes, and purified by agarose gel electrophoresis, if necessary. There
are three methods by which the transgene and plasmid DNA can be prepared. In the
first method, they can be digested with restriction enzyme(s) that yield identical
overhangs (sticky ends) at the 5’ and 3’ ends of both. Since these identical overhangs
are complementary with each other, the annealed fragments can be ligated together
with DNA ligase. In general, we used a transgene-containing fragment to plasmid
ratio of 5 to 1 to increase the probability of transgene insertion into the plasmid. A
problem associated with this method obligation is the high self-ligation of the
plasmid alone. A dephosphorylation step may be included by treating the linearized
plasmid with alkaline phosphatase. The incidence of plasmid self-ligation can be
greatly reduced without the phosphate groups at the termini. Another problem
associated with this method of ligation is that, since all the overhangs are identical,
the fragment could be inserted into the plasmid in either orientation. If the transgene
fragment is a cDNA sequence, it must have the same orientation as the promoter on
the plasmid DNA. The orientation of the transgene insert can be confirmed using
restriction enzyme digestions and agarose gel electrophoresis. The second method for
preparing the transgene fragments and linearized plasmid DNA is to digest them with
two different restriction enzymes so that they have compatible ends with each other
but without the ability for self-ligation. Since there is only one orientation in which
the transgene can be inserted, this method of ligation is very efficient. The third
method for preparing transgene fragments and linearized plasmid DNA is to blunt-
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end the DNA after restriction enzyme digestion. This is especially necessary when
the protruding ends of the transgene fragment are not compatible to the ends of the
linearized plasmid. Blunt-ending of the transgene fragment can be performed by
either filling in the ends using a DNA polymerase or by trimming the ends using a
single strand DNA exonuclease. Blunt-end ligation of DNA is a difficult cloning
strategy due to the very high levels of plasmid self-ligation. It is much less efficient
than the ligation method using compatible sticky ends. Dephosphorylation of the
linearized plasmid vector by phosphatase may help to decrease the incidence of self
ligation and to improve the transgene insertion efficiency. Furthermore, in
experiments when the protruding ends of the insert are not compatible with the ends
of the plasmid vector, an alternative cloning strategy may be applied. In this strategy,
restriction sites that are used to linearize the plasmid vector are inserted into the PCR
primers, which are then used to amplify the transgene insert. Following restriction
digestion by the same enzyme(s), both the PCR fragment containing the transgene
and the plasmid vector have compatible ends generally resulting in greatly improved
ligation efficiency. After the ligation step, the DNA is transformed into competent
bacteria (usually E. coli DH5oc) either by the heat shock method or by
electroporation. Positive clones are identified using restriction digestion of isolated
plasmids and examination of fragment lengths separated by agarose gel
electrophoresis.
Bacterial Transformation with Plasmid DNA
The transformation of circular plasmid DNA into bacteria (E. coli) was performed
using either the heat shock method or electroporation. We used the following
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protocol, which was modified from Inoue et al. (1990), to prepare competent E. coli
for plasmid transformation by heat shock. A single colony of E. coli DH5a was used
to inoculate 500 ml of SOB medium in a 2 L flask. Cells were grown at room
temperature with vigorous shaking (250 rpm) to an ODeoo of 0.6. The cells were
incubated on ice for 10 min before being pelleted by centrifugation at 3,000 rpm for
10 min at 4 °C. We resuspended the pellet in 160 ml ice-cold TB buffer, and placed
it on ice for 10 min. We centrifuged the cells again at 3000 rpm for 10 min at 4 °C.
The cell pellet was then gently resuspended in 40 ml of ice-cold TB. During gentle
swirling, 2.8 ml of 0.2 pm-filtered DM SO were added to the cells. After incubation
on ice for another 10 min, the cells were aliquoted into Eppendorf tubes (200 pi each)
and immediately frozen in liquid nitrogen. Frozen competent E. coli bacteria were
stored in a -80 °C freezer. To transform plasmid DNA into competent E. coli by heat
shock, frozen competent cells were thawed on ice for 10 min. Plasmid DNA (<20 pi
in volume) was added to the cells, and the mixture was kept on ice for another 30
min. At the end of that time, the plasmid DNA/E1. coli mixture was heat shocked in a
42 °C water bath for 30 sec. After the addition of 0.8 ml of SOC, the cells were
transferred to a 37 °C incubator and shaken vigorously for 1 h. At the end of
incubation, the desired amount of transformed cells was spread on agar plates with
antibiotic selection and incubated in the 37 °C incubator overnight. On the second
day, colonies were counted to determine transformation efficiency.
To prepare competent E. coli for plasmid transformation using electroporation, 1 L of
SOB was inoculated with a single colony of bacteria, and the bacterial cells were
cultured at 37 °C with moderate shaking (150 rpm) to an ODeoo of 0.3. The bacterial
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cells were kept on ice for 30 min, and then pelleted by centrifugation at 3000 rpm for
10 min at 4 °C. Bacterial cells were washed sequentially with the following: an equal
volume of ice-cold 1 mM HEPES (pH 7.0), an equal volume of ice-cold water, onehalf volume of ice-cold water, and finally 30 ml of ice-cold 20% glycerol washing
solution. After each washing step, the bacteria were pelleted by centrifugation at
3000 rpm for 10 min at 4 °C. At the end of washing procedures, the pellet was gently
suspended in 2 ml ice-cold 10% glycerol stock solution. The bacterial suspension
was then aliquoted (50 pi each) into Eppendorf tubes and frozen in liquid nitrogen,
and then stored in a -80 °C freezer. To transform plasmid DNA into E. coli by
electroporation, competent cells were thawed on ice for 10 min. Plasmid DNA (<5
pi) was added to the cells. The mixture was transferred into a 0.1 cm electroporation
cuvette (Bio-Rad, Hercules, CA) and electroporated at 1.8 kV, 25 pF, and 200
Q using a Gene Pulser apparatus and Pulse Controller (Bio-Rad, Hercules, CA).
Immediately after electroporation, 0.9 ml of SOC was added to the cells, and the cells
were incubated in a 37 °C incubator with shaking for 1 h. At the end of incubation, a
desired amount of bacterial cells was spread on agar plates with antibiotic selection.
After overnight incubation at 37 °C, colonies were counted to determine
transformation efficiency.
Purification of the DNA from an Agarose Gel
We used the GENECLEAN DNA purification kit (BiolOl, Vista, CA) to purify
the DNA from a TAE agarose gel following a modified protocol. A slice of agarose
gel (<500 pi in volume) containing the plasmid DNA was excised under UV
illumination and transferred to an Eppendoff tube. Three volumes of 6 M Nal
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solution was added to the gel slice, and placed in a tube in a 65 °C dry bath for 5 min
to melt the gel. The tube was then transferred to ice for 10 min. Then, 20 pi of
glassmilk were added, and mixed by gentle vortex. The tube was then kept on ice for
10 min to allow binding between the glassmilk and the DNA. The glassmilk/DNA
complex was then pelleted by centrifugation at 12,000 rpm for 5 sec. The supernatant
was removed and the pellet washed with 1 ml of New Wash solution. The wash and
pelleting steps were repeated twice. The DNA was eluted in 20 pi of water and
incubated at 65 °C for 2 min. After elution, the glassmilk was pelleted by
centrifuging at 12,000 rpm for 5 sec. The supernatant containing the DNA was
carefully transferred to a new tube.
Large-Scale Plasmid DNA Purification
We used the QIAfilter Maxi Prep kit (Qiagen, Valencia, CA) to purify large
amounts of plasmid DNA (300 pg to 1 mg) from transformed E. coli using the
following protocol. Bacteria were inoculated in 250 ml of LB medium in the
presence of antibiotic selection and cultured overnight at 37 °C with vigorous shaking
(250 rpm). The bacteria were harvested by centrifugation at 6000 rpm for 15 min.
The bacteria were resuspended in 10 ml of Buffer PI (containing RNase A). Then,
10 ml of Buffer P2 were added and mixed well by swirling the centrifuge bottle
clockwise and counterclockwise. Ten ml of ice-cold Buffer P3 were added and
mixed well by swirling the bottle. The lysate mixture was then transferred to the
barrel of the QIAfilter cartridge and incubated at room temperature for 10 min. Ten
ml of Buffer QBT were used to equilibrate a QIAGEN-tip 500 column. The plunger
was inserted into the QIAfilter cartridge to filter the cell lysate into the equilibrated
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QIAGEN-tip 500 column. After allowing the lysate to flow through the column, the
column was washed with 30 ml of Buffer QC. This step was repeated once. The
purified plasmid DNA was eluted into a new 50 ml centrifuge tube using 15 ml
Buffer QF. Isopropanol (10.5 ml) at room temperature was added. This was mixed
well and immediately centrifuged at 11,500 rpm for 30 min at 4 °C. The plasmid
DNA pellet was washed with 5 ml of 70% ethanol. After centrifugation, the pellet
was air-dried and redissolved in 200 pi sterile water. The DNA concentration was
determined using a spectrophotometer at 260 nm.
Mammalian Cell Transformation with Plasmid DNA (Calcium Phosphate
Precipitation Method)
Transformation of the double-stranded plasmid DNA into mammalian cells was
performed using the calcium phosphate transformation method (Profection
Mammalian Transfection Systems, by Promega, Madison, WI). The calcium
phosphate transformation method can be used both for transient transformation as
well as for long-term stable transformations of adherent cell lines. This technique
involves the coprecipitation of plasmid DNA with calcium phosphate crystals, formed
by mixing CaCf and HEPES phosphate buffer. Graham and van der Eb (1973) were
the first to show that the entrance of DNA into mammalian cells is greatly enhanced
when coprecipitated with calcium phosphate crystals. Since then, plasmid DNA
transformation using the calcium phosphate precipitation method has been
successfully demonstrated in a large variety of cell lines. Therefore, it is routinely
used as the method of choice for both transient and stable transformations.
The following is a brief description of the protocol of the calcium phosphate
precipitation method we used for mammalian cell transformation. The cells were
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seeded in 10 cm culture dishes, and grown to 50-80% confluency. Three hours before
the transformation experiment, the old medium was replace with fresh growth
medium. Frozen HBS buffer (containing HEPES) was thawed and brought to room
temperature. Two 15 ml tubes were prepared. To the first tube, 62 pi of 2 M CaCb
and plasmid DNA were added. The volume was adjusted to 500 pi using sterile
water. To the second tube, 500 pi of 2 x HBS were added. Working in a tissue
culture hood, the DNA CaCb mixture from the first tube was added dropwise to the
HBS in the second tube, which was continuously vortexed. The mixture was
incubated at room temperature for 30 min. After briefly vortexing the mixture again
it was added dropwise to the cells. The cell culture plates were incubated at 37°C for
12 to 17 hours after transformation, at which time fresh medium was added. The
transformed cell cultures were analyzed 48 to 72 hours after transformation for
protein expression.
Luciferase Assays
The activity of recombinant Rue was assayed using the following protocol.
Mammalian cells were suspended in 500 pi of luciferase assay buffer (0.5 M NaCl,
0.1 M potassium phosphate, 1.0 mM EDTA, pH 7.5) (Matthews et al. 1977).
Coelenterazine substrate (Molecular Probes, Eugene, OR, and Nanolight Technology,
Pinetop, AZ) was added to the samples to a final concentration of 0.1 to 10 pM, and
the samples were then analyzed using a luminometer, a spectrophotometer, or a low
light imager. Since coelenterazine can freely diffuse into mammalian cells, cell lysis
is not required to assay intracellular Rue activity. However, if desired, a luciferase
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lysis buffer (125 mM Tris, pH 7.6, 0.5% Triton X-100) may be used to lyse cells prior
to luciferase assays.
Fluorescence Microscopy
The principle of fluorescence microscopy is based on the fact that fluorescent
molecules (or fluorophores) absorb light of a given wavelength and subsequently emit
light at a longer wavelength. The fluorescence microscope is a modification of the
conventional optical microscope. There are two types of fluorescence microscopes:
epifluorescence microscopes and transmission fluorescence microscopes. Three
components are needed to construct a fluorescence microscope: 1) a source of
excitation light, usually a mercury arc lamp, that emits strong short wavelength light;
2) an excitation barrier filter, which excludes undesirable wavelengths of light and
allows passage of only the one that excites the fluorophores; 3) an emission barrier
filter, which allows the passage of only the long wavelength light emitted from the
fluorophores. The fluorescence image can be viewed through the eyepiece or through
a CCD camera. The quality of the images is dependent on the choice of filter set.
In our laboratory, we used an upright Carl Zeiss Axioplan microscope (Thomwood,
NY) equipped with a Model 1200 power supply for visualizing fluorescence of cells
on slides. Cells were first grown on sterile coverslips, which were precoated with a
layer of poly lysine, in tissue culture dishes. Before transfer to glass slides, the cells
can be fixed with either 4% formaldehyde or with 70% ethanol. However, fixation is
not necessary. Then, the coverslip was picked up by a pair of sterile forceps and laid
down on a glass slide with the cell-coated surface facing the slide. The coverslip was
then sealed with Fluoromount-G* Slide Mounting Medium (Fisher Scientific, Tustin,
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CA), but this step is not necessary. We used both an inverted Carl Zeiss Axiovert
TV 100 microscope equipped with a Model 1600 power supply and a 35 mm camera
and a Leica MZ8 stereo fluorescence microscope equipped with a SONY DKC-5000
3 CCD digital camera for visualizing fluorescence in tissue culture dishes.
Mammalian Cell Microencapsulation by Alginate/PLL
The detailed methods of cell microencapsulation have been described previously
(Martinsen et al. 1992; Read et al. 1999; Serp et al. 2000). In our laboratory, the
following procedures were used in a typical cell encapsulation experiment. The cell
microencapsulation device (Fig. 1.10) used in our laboratory is the Encapsulator
(Inotech AG, Switzerland). The autoclaved encapsulation cylinder was assembled
under a laminar flow hood. The encapsulation cylinder was filled with 225 ml of
sterile polymerization solution. A cell culture with approximately 5 x 106 cells was
centrifuged and the pellet was suspended in 7.5 ml of sterile MOPS washing buffer.
The cell suspension is added to 15 ml of 1.5% sodium alginate solution, which has
been prefiltered through a filter with pore size of 50 pm, and mixed gently so as not
to form bubbles. A 60 ml syringe was filled with the cell-alginate suspension and
attached to the syringe pump. Control of the flow of alginate to the Encapsulator
nozzle was achieved by adjusting the speed of the syringe pump, which was initially
set at 14.3 units. The turbo button was turned on to initiate the flow of cell-alginate.
After initiation of flow, the syringe pump speed was reduced to about 10.9 units. The
vibration frequency used to create individual beads was set initially at 700 Hz for the
300 pm-sized nozzle. The electrostatic charge system was turned on and the initial
voltage was set to 1 kV. The electrostatic charge aids in dispersing the beads. The

74

pump speed and/or the vibration frequency were adjusted in combination to achieve a
stable bead chain with beads of the desired size flowing down into the bypass cup.
Increasing the frequency and decreasing the speed of the syringe pump results in
formation of smaller beads and vice versa. After the formation of the desired stable
bead chain, the bypass cup was removed allowing the bead chain to fall into the
polymerization solution, which was constantly agitated by a stir bar. The electrically
controlled bead disperse point was adjusted to about 5 cm below the electrode.
Shortly before the syringe pump was empty, the bypass cup was moved back into the
bead stream. The syringe pump control, vibration control, and electrostatic charge
control were all turned off at this point. The beads were allowed to polymerize for 5
min under constant stirring. The drain valve was opened to release the alginate beads
encapsulating cells into a collection flask. The beads were allowed to settle to the
bottom of the flask for 5 min. Excess polymerization solution was carefully
aspirated, leaving just sufficient liquid to cover the cell-alginate beads. Fifty ml of
0.05% PEL, which had been prefiltered through a 0.2 pm filter, was added to the cellalginate beads, and stirred for 10 min. The aspiration procedure was repeated again.
The cell-alginate/PLL beads were washed with 100 ml of MOPS washing buffer for 1
min and again with 150 ml of MOPS washing buffer for 5 min. The washing solution
was removed and 50 ml of 0.03% of sodium alginate solution was added to the beads,
and stirred for 5 min. The beads were sequentially washed again with 100 and 150
ml of MOPS washing buffer for 1 and 5 min, respectively. After removing the liquid,
cell culture medium was added to the beads. While being agitated by swirling, the

75

medium containing the beads was aliquoted into cell culture dishes. The
alginate/PLL-encapsulated cells were incubated at 37 °C in the presence of 5% CO2.
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CHAPTER THREE
STUDY OF INDUCIBLE GENE EXPRESSION IN VIVO USING A RENILLA
LUCIFERASE - AEQUOREA GFP (RUC-GFP) FUSION GENE CONSTRUCT
Abstract
In this study, we used a steroid-induced promoter activation system as a
molecular switch to study exogenous activation of transgene expression. This
promoter activation system consists of three components, (1) a steroidal inducer drug,
mifepristone (RU486), which binds the (2) chimeric transcription factor complex,
consisting of the mutant human progesterone receptor fused to the yeast GAL4 DNAbinding domain and the herpes simplex virus protein VP 16 activation domain, and (3)
a synthetic promoter, consisting of a series of GAL4 recognition sequences upstream
of the adenovirus major late E1B TATA box, linked to a Renilla luciferase
Aequorea green fluorescent protein (GFP) fusion gene (ruc-gfp). The transcription of
the promoter-marker gene cassette is activated by the drug (mifepristone)-bound
chimeric transcription factor complex. Monitoring of induced gene expression was
carried out by a low light video camera and a UV microscope to detect luciferase and
GFP activation, respectively. Using this activation system, we showed that robust
and significant levels (close to 30-fold) of ruc-gfp marker gene expression were
achieved in cell cultures. The activation of gene expression is mifepristone
dependent and is strictly regulated by the chimeric transcriptional activator protein.
The establishment of this rapid and noninvasive method of monitoring inducible gene
expression in cell cultures will aid investigators in developing imaging procedures to
continuously follow gene function in developing organisms and the location of
therapeutic proteins during gene therapy procedures. The method should also be of
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general use in gene therapy investigations for simultaneous monitoring of the
expression levels of light-emitting proteins and therapeutic proteins originating from
the activation of identical promoters.
Key Words
Inducible gene expression • Renilla luciferase • Aequorea GFP • Cellular
implantation
Introduction
Numerous eukaryotic genes have been successfully overexpressed in cell cultures
and in animal models. This technology allows investigators to study gene functions,
and address some fundamental questions that could potentially promote the
establishment of defined gene therapy procedures. However, constitutive expression
of proteins that may be toxic or may have negative effects on cell growth and
organism development is not desirable, and the accumulation of such proteins could
have detrimental effects. Furthermore, experiments to study the function of
individual proteins during specific stages of development of an organism in a
spatially and temporally controlled manner cannot be performed in transgenic animals
that carry a constitutive promoter driven gene construct. Several laboratories have
reported the design of inducible eukaryotic gene expression systems, which include
the tetracycline-regulated systems (Gossen and Bujard, 1992), an ecdysone-inducible
system (Christopherson et al. 1992; No et al. 1996), an antiprogestin-regulated
promoter activation system (Wang et al. 1994; Delort and Capecchi 1996), and a
dimerization-based regulatable system (Belshaw et al. 1996; MacCorkle et al. 1998).
Among those listed, the two-plasmid-based “GeneSwitch” promoter activation
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system (Wang et al. 1994) has consistently given the highest levels of target gene
expression upon the addition of a progesterone antagonist (mifepristone) as the
inducer drug. In this system, one of the two plasmids carries the chimeric
transcription factor cassette, which is expressed constitutively under the CMV
promoter (chimeric activator plasmid), and the second plasmid harbors the inducible
promoter-target gene fusion cassette (reporter plasmid). The binding of mifepristone
to the chimeric transcription factor in the cells allows the binding of the
transcriptional factor to the GAL4 promoter, activates the inducible promoter and
initiates transcription of the target gene. So far, using this promoter activation
system, transgene expressions of secreted human placental alkaline phosphatase
(SEAP) (Abruzzese et al. 1999), human growth hormone (hGH) (Burcin et al. 1999),
transforming growth factor pi (TGFpl) (Wang et al. 1999), vascular endothelial
growth factor (VEGF) and erythropoietin (Abruzzese et al. 2000), inhibin A (Pierson
et al. 2000), and growth hormone releasing hormone (GHRH) (Draghia-Akli et al.
2002) have been successfully demonstrated. This regulatable system has been shown
to be stable both in cell cultures and in transgenic animals. Furthermore, the
induction drug mifepristone does not have toxic effects on humans when it is
administered over a long period of time at dosages up to 20 mg/kg (~ 18.6 pM)
(Handerson 1997).
Using the two-plasmid-based Gene Switch promoter activation system, we studied
the induction and expression of a Renilla luciferase-GFP (ruc-gfp) fusion gene
construct. Renilla luciferase is an enzyme from a soft coral, Renilla reniformis
(Lorenz et al. 1991). It catalyzes a chemical reaction using coelenterazine and
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oxygen, which emits light at a peak wavelength of approximately 485nm. Due to the
simplicity of this process, which allows indirect monitoring of luciferase activity by
observing light emission, luciferase has been used as a marker gene in gene
expression studies (Yu et al. 2001; Bhaumik and Gambhir 2002; Greer and Szalay
2002). Such light-emitting events can be quantified by imaging techniques and
correlated directly with luciferase levels in cells. GFP is a chromophore-containing
protein whose cDNA has been isolated and sequenced from the jellyfish ,4 eg worn?
victoria. Unlike luciferase, GFP does not require any substrates or cofactors to be
functional. GFP fluorescence can be monitored within living cells using an excitation
source provided by UV light. Quantification of GFP signals may be difficult due to
poor sensitivity of currently available assays. Nevertheless, since an external
substrate is not required for GFP fluorescence in living tissues, use of GFP for
studying gene expression in living organisms would be potentially advantageous.
The Ruc-GFP fusion protein has been shown to retain both luciferase and GFP
functions in cell cultures (Wang et al. 1997; Liu et al. 2000). We employed the RucGFP fusion protein as marker to monitor gene activation in real time, in living cells
and animals and to locate GFP coexpression in individual cells.
Here we describe the construction of a reporter plasmid, which carries a fusion
gene, ruc-gfp encoding a chimeric protein with luciferase and GFP activity. This
plasmid was cotransformed with the chimeric activator plasmid which carries the
chimeric transcriptional activator expression cassette into COS cells. The fusion gene
expression was studied by exogenous addition of mifepristone. We showed that
significant levels of ruc-gfp marker gene expression were achieved in cell cultures.
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The establishment of this rapid and noninvasive method of monitoring inducible gene
expression will aid investigators in developing imaging procedures in future studies
to continuously follow gene function in developing organisms and trace the location
of therapeutic proteins during gene therapy procedures.
Materials and Methods
Construction of Plasmid Vectors
Plasmid DNA pl7x4-TATA-CAT (from Dr. Y. Wang, Department of Cell
Biology, Baylor College of Medicine, Houston, TX) was digested with Xhol and
EcoRI. The ends of the larger fragment were blunted with T4 DNA polymerase, and
gel-purified using a Geneclean kit (Qbiogene, Inc., Carlsbad, CA). In a parallel
reaction, ^CEVA-ruc-gfp (Wang et al. 1997) was double digested with Sail and Kpnl
and blunted with T4 DNA polymerase. The smaller fragment containing the ruc-gfp
sequence was similarly gel-purified. The purified fragments were then ligated
together to create the resulting plasmid named pl7x4-TATA-rwc-g/p. Using
restriction digestions, the correct orientation of the fragments was confirmed.
Plasmid ^CX-ruc-gfp was constructed based on pCX-EGFP (Okabe et al. 1997).
Plasmid pCX-EGFP was digested with EcoRI. The EcoRI fragment containing the
EGFP cDNA was excised, and replaced with the Pmel fragment (containing the rucgfp cDNA sequence) from pcDNA-rwog/p.
Plasmid pUAS-rwc-g/p was generated by inserting a Pmel fragment of ruc-gfp
from pcDNA-rwc-g/p (Wang et al. 1997) into the T4 DNA polymerase-blunted EcoRI
fragment of pUAS (Delort and Capecchi 1996).
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Cell Cultures and Transient Transfection Assays
Six-well microtiter plates were seeded with 5 x 105 COS cells (monkey kidney
cells transformed by SV40 virus). Cells were grown overnight in DMEM
supplemented with 10% fetal bovine serum at 37 °C with 5% CO2. On the second
day, the culture medium was changed two hours before plasmid DNA addition. The
cells were then transformed with designated amounts of DNA, using the calcium
phosphate precipitation method (Profection Mammalian Transfection Systems,
Promega, Madison, WI). Twenty-four hours after DNA transformation, mifepristone
(Steraloids, Inc., Newport, RI) dissolved in absolute ethanol was added to the cultures
to initiate induction of gene expression from the inducible promoter. Following
mifepristone induction, aliquots of the cell cultures were tested for luciferase activity
(using coelenterazine as substrate) and for GFP fluorescence signal (using a Zeiss
fluorescence microscope).
Luciferase Assays
The culture medium in each well was removed by aspiration and replaced with 1
ml of luciferase assay buffer (0.5 M NaCl; 1 mM EDTA; and 0.1 M potassium
phosphate, pH7.4) to which was added 2 pi of coelenterazine from a 0.5 pg/pl
methanol stock solution. The cells were then imaged using a Hamamatsu Argus 100
Low Light Video Camera (Hamamatsu Instruments, Hamamatsu, Japan) or a
Nightowl Low Light Imager (EG&G-Perkin Elmer, Boston, MA). The light emission
from luciferase assays was also monitored using a Turner TD 20e luminometer
(Turner Designs, Sunnyvale, CA).
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Results
Induced Expression of Ruc-GFP Fusion Protein in Transiently Transfected Cells
To study the inducible system, we constructed a ruc-gfp reporter plasmid based
on the reporter vector of the promoter activation system by inserting the ruc-gfp
fusion gene construct downstream to the inducible promoter (Fig.3.1). The
mifepristone-dependent Ruc-GFP fusion protein expression was tested by detecting
luciferase activity in cell cultures. COS cells were either cotransformed with both
reporter and transcription activator plasmids or transformed with reporter plasmid
construct alone. The inducer mifepristone drug was delivered 24 hours after DNA
transformation to initiate transcriptional activation of marker gene expression. The
promoter activation by the hybrid transcription factor bound mifepristone complex
was allowed to proceed over a 24- to 36-hour period of time, and then the cells were
tested for luciferase or GFP expression. The culture medium was removed by
aspiration and the cells were washed with serum-free medium. To avoid cell loss or
cell damage, the luciferase substrate coelenterazine was added directly in luciferase
assay buffer to the plates. Luciferase activity was quickly monitored in attached cells
with a Hamamatsu Low Light Video Camera, a Nightowl Low Light Imager, or
quantified by the use of a Turner luminometer. Results from such experiments
showed that the induction levels of luciferase expression obtained were ~28-fold
higher than that of the uninduced controls (Fig. 3.2). These induction levels did not
reach the ~ 50-fold levels obtained with the chloramphenicol acetyltransferase
reporter gene by Wang et al. (1994).
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Fig. 3.1. Description of the plasmid components of the mifepristone activatable
Ruc-GFP expressing promoter system. The chimeric transcriptional activator
plasmid construct (PAP CMV-GL914VPc’SV) encodes a hybrid protein consisting of
a mutated human progesterone binding protein fused to the carboxyl terminus of a
yeast GAL4-DNA binding domain (GAL4-DBD) and to the amino terminus of a viral
transcription trans-activator (VP 16). This expression cassette is under the control of a
CMV promoter. The synthetic promoter in the reporter plasmid (pl7x4-TATA-rwo
gfp) consists of four GAL4 upstream response elements and a TATA box, controlling
the expression of the ruc-gfp reporter gene. Ruc-GFP expression from the reporter
plasmid can be induced by the chimeric activator protein in the presence of the
inducer drug mifepristone.
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Chimeric activator plasmid (PAP CMV-GL914VPc’SV):
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Fig. 3.2. Comparison of luciferase expression levels in cells transformed with
both plasmids of the inducible promoter system or with the reporter plasmid
alone. Approximately 5 x 106 COS cells were seeded onto each of the three 10-cm
plates the night before transformation. The cells in two plates were each co
transformed with 9 pg of pl7x4-TATA-rwc-g/p and 9 pg of PAP CMVGL914VPc’SV plasmid DNAs. The cells in the third plate were transformed with 9
pg of pl7x4-TATA-rwc-g/£> DNA alone as the control. The cells were cultured at 37
°C for 24 hours followed by the addition of mifepristone, to a final concentration of
250 nM, to one of the two plates of cells that have been transformed with both
plasmids, or to the cells that have been transformed with the reporter plasmid alone.
Thirty-six hours after mifepristone addition, the cells from all three plates were tested
for luciferase expression in the presence of coelenterazine (1 pg / 10 ml plate) as
substrate. Light emission from cells were reported as counts/sec.
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The levels of luciferase gene expression obtained from the inducible vector
system were also compared with data obtained from experiments using a strong
constitutive promoter, such as the chicken p actin promoter with CMV enhancer,
linked to the ruc-gfp marker gene cassette carried on the pCX-ruc-gfp plasmid DNA
in COS cells. In spite of an approximately 28-fold induction, the luciferase signal
from the inducible system was approximately 4-fold less intense than that emitted
from the P actin promoter driven ruc-gfp fusion gene construct (data not shown). This
finding was not surprising, since the chicken p actin promoter was found to be the
strongest promoter in COS cells and showed the highest levels of constitutive RucGFP expression in earlier experiments (data not shown).
Mifepristone-induced GFP expression of ruc-gfp fusion cassette from transiently
transformed COS cells was also monitored using a fluorescent UV microscope (Fig.
3.3). Approximately 18% of the cells exhibited green fluorescence upon addition of
mifepristone to the growth medium at a final concentration of 250 nM. On the other
hand, virtually no GFP signal was observed in control cells in the absence of the
mifepristone inducer drug. The percentage (~18%) of GFP positive cells transiently
transformed with the inducible vector system was markedly lower than the percentage
(~30%) of GFP-positive cells transiently transformed with an equimolar amount of
marker gene plasmids using pCX-ruc-gfp with the chicken P-actin promoter. Since
we used transient DNA transformation procedures, we only followed the induction
levels to a maximum of 38 hours after introduction of mifepristone. Therefore, the
percentage of GFP-positive cells may be further increased by extending the induction
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Fig. 3.3. Comparison of GFP expression in COS cells transformed with both
plasmids in the presence or absence of mifepristone induction. Approximately 5
x 106 COS cells were seeded on two 10-cm culture dishes. On the second day, the
cells were transiently cotransfected with 40 pg of pl7x4-TATA-rwc-g/p and 2 pg of
PAP CMV-GL914VPc’SV. Twenty-four hours following transfection, mifepristone
was added to a final concentration of 250 nM to one of the two plates for
transcriptional induction (A). No mifepristone was added to the control plate (B). An
additional 24 hours later, the cells were visualized under a Zeiss fluorescence
microscope to observe GFP expression.
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time, or by repetitive addition of mifepristone, to allow enhanced transcriptional
activation.
The Activation of the Inducible Promoter Driven ruc-gfp Fusion Gene Expression
is Strictly Dependent on the Presence of the Chimeric Transcription FactorEncoding Plasmid DNA
Since the chimeric transcriptional activator is under the control of a constitutive
CMV promoter, it is important to verify the expression levels of Ruc-GFP driven by
the inducible promoter without the addition of mifepristone to obtain the basal levels
of the inducible promoter. To determine the basal expression levels, COS cells were
seeded 24 hours before DNA transformation. Different ratios of the transcriptional
activator and Ruc-GFP reporter plasmids were cointroduced into the cells (Fig. 3.4).
The concentration of mifepristone (final concentration of 250 nM) was kept constant.
After analyzing the transformation results, it became evident that by limiting the
amount of transcriptional activator encoding plasmid DNA, the basal expression from
the inducible promoter could be kept at a relatively low level. A reporter plasmid to
activator plasmid DNA ratio ranging from 20:1 to 100:1, yielded the most optimal
induction levels while maintaining a basal level of leakiness at a minimum. The
addition of the chimeric activator and reporter plasmid DNA in a 1:1 ratio resulted in
higher basal levels and therefore diminished the induced activation of transcription.
These results were repeatable in several experiments (Fig. 3.5). Not surprisingly,
when the reporter and activator plasmids were used in a ratio of 500:1, the basal level
of gene expression was kept at a minimal level, but overall induction levels were also
smaller. Interestingly, the presence of an excessive amount of chimeric activator
DNA to reporter DNA in a ratio of 20:1 did not result in increased reporter gene
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Fig. 3.4. The activation of the inducible promoter driven ruc-gfp fusion gene
expression is dependent on the presence of the chimeric transcriptional
activator-encoding plasmid DNA. 5 x 105 COS cells were aliquot equally and
seeded into twelve 3-cm plates 16 hours before DNA transformation. Fixed amounts
(2.5 pg) of reporter plasmid (pl7x4-TATA-rwc-g/p) and various amounts of chimeric
activator plasmid (PAP CMV-GL914VPc’SV), as indicated by the numerical ratios,
were co-transformed into the cells. For each ratio, cells from one of the two plates
were treated with mifepristone (250 nM in final concentration) for 36 hours, while the
other plate served as the control.
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Fig. 3.5. Effect of mifepristone concentration on promoter activation
determined by luciferase assays. (A) Approximately 5x10 COS cells were
seeded onto each of the nine 10-cm culture dishes. After 24 hours of cell growth, the
cells in each plate were cotransformed with 9 pg of pl7x4-TATA-rwog/p and 9 pg of
PAP CMV-GL914VPc’SV plasmid DNAs. Following further culture for 24 hours,
increasing amounts of mifepristone (125, 250, 500, 1000, 4000, 16000, 32000, and
64000 pM in final concentration) were added to the cells to trigger transcriptional
activation. Thirty-six hours after mifepristone addition, cells were trypsinized and
transferred to 12-well titer plates. One ml of luciferase assay buffer containing 1 pg
of coelenterazine was added to each well. Luciferase activity was recorded indirectly
as relative light units or counts per second based on light emitting chemiluminescence
reactions. (B) A similar mifepristone dose response experiment as shown in (A)
except different ratios of chimeric transcriptional activator (2 pg) and reporter (40 pg)
plasmid DNAs (i.e. ratio of 1:20) were used.
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expression. This may be the result of saturating the supply of the inducible promoterreporter gene construct with chimeric transcriptional activator proteins. Further, the
expression of Ruc-GFP marker, in cells transformed with reporter plasmid DNA
alone, was at same level with or without the addition of mifepristone. This finding
suggests that non-specific binding of other transcription factors to the inducible
promoter region occurred without the inducer drug (data not shown). Therefore, the
activation of reporter gene transcription by the chimeric activator protein is strictly
mifepristone-dependent.
Determination of Mifepristone Concentration Required for Maximal Inducible
Promoter Activation
We set out to determine the optimal concentration of mifepristone that will allow
the highest level of activated gene expression. Cells transiently transformed with
chimeric activator plasmid DNA and reporter DNA were treated with increasing
concentrations of mifepristone (Fig. 3.5). By comparing data from several
experiments, we consistently observed the highest levels of reporter gene expression
in the presence of 250 nM mifepristone. Based on these findings, we continued to
use a 250 nM concentration of mifepristone in all subsequent experiments.
Kinetics of the Inducible System
We further examined the time course of mifepristone required for activation of the
inducible promoter driven Ruc-GFP expression in cell cultures, by measuring
luciferase based photon emissions after the addition of the substrate coelenterazine
(Fig. 3.6).

Activation of Ruc-GFP expression was evident just three hours after

exposure of cell cultures, transformed with both activator and reporter plasmids, to
mifepristone. Following the treatment with mifepristone, the activated gene
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Fig. 3.6. Determination of mifepristone promoter activation in real time. COS
cells from two 10-cm plates (0.6 x 10 each plate) were transformed with 60 pg of
pl7><4-TATA-rwc-g/p and 3 pg of PAP CMV-GL914VPc’SV plasmid DNAs using
the calcium phosphate precipitation method. Twenty-four hours after transformation,
the cells were aliquot onto twenty-six 3-cm plates. Mifepristone was added by gently
mixing into the media of half the plates (13) to start induction. The other half
numbers of plates were used as no-induction controls for each time point taken. At
each time point, two plates (one with and one without mifepristone induction) were
withdrawn from the incubator, and the luciferase activity was determined (panel A).
Panel B shows the photon collection image from the light emitting cells in two 3-cm
plates measured at the 38-hour induction time point using the Nightowl Low Light
Imager. One half pg of coelenterazine was used for luciferase assay in each 3-cm
plate.
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expression occurred over a linear range during the 17-hour exposure time. Seventeen
hours after mifepristone addition, the luciferase activity began to plateau, although
the light signal did continue to increase when measurements were made up to 38
hours. In contrast, in the absence of mifepristone, cells containing both plasmid
DNAs exhibited only basal levels of luciferase expression throughout the experiment.
Therefore, the induction of transcriptional activation in the presence of the inducer
mifepristone worked in a time-dependent fashion.
Discussion
This paper describes the use of a promoter activation system, which is a threecomponent gene expression system that is exogenously regulatable. This system is
functional both in mammalian cell cultures and in live animals (data not shown). The
essential feature of these experiments is the use of a ruc-gfp fusion gene construct
linked to the inducible promoter that enables us to monitor the kinetics of the
exogenously added, inducer drug-regulated, gene expression process through
noninvasive procedures, i.e. by monitoring luciferase gene expression using a lowlight video camera or GFP gene expression in individual cells based on fluorescence.
Besides allowing noninvasive visualization, the second advantage of the Ruc-GFP
marker protein is that the dual labeling allows gene expression to be quantitatively
compared using luciferase, based on photon emission, and allows gene expression in
individual cells to be localized based on GFP fluorescence. A third advantage of the
Ruc-GFP based promoter activation system is that one can quantitatively analyze
expression of other target-genes-of-interest indirectly based on Ruc-GFP markers. In
order to express the target protein and the Ruc-GFP fusion protein in the same cell in
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close to equimolar amounts, the expression of both genes must be activated by the
same promoter. This can be achieved by using one inducible promoter linked to the
target gene followed by an internal ribosomal entry site (IRES) linked to the ruc-gfp
fusion gene. In this way, activation of target gene expression can be indirectly
monitored based on downstream Ruc-GFP marker protein expression. In addition to
IRES, a bi-directional promoter, the tetracycline-regulated bi-directional promoter in
the pBI cloning vector (Clontech, Palo Alto, CA), may be used to simultaneously and
quantitatively express the target gene and the ruc-gfp fusion gene in the same cell.
An alternative solution to using IRES and a bi-directional promoter is to construct a
second fusion gene by fusing the target gene in frame to either luciferase or GFP
cDNA or to both as long as such a fusion event does not interfere with the original
function of any of the fusion partners. Since there is a one-to-one ratio between the
two genes, expression from the target gene can be at least semiquantitatively
estimated based on luciferase light emission or by determining the GFP fluorescence
quantitatively. The obvious disadvantage of using the fusion strategy is that for each
gene-of-interest, a new fusion gene needs to be constructed, which is time consuming.
However, once such a fusion is completed and characterized, the gene constructs
could have great potential in functional studies.
The feasibility of using IRES, enhanced GFP, and fluorescence activated cell
sorting (FASC) for systematically characterizing exogenous gene functions in
mammalian cells has been demonstrated very recently by Garton et al. (2002).
Similarly, with the aid of IRES, a bi-directional promoter, and light-emitting proteins,
a close to uniform population of transformed cells with low basal but high induction
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levels of gene expression can be isolated based on luciferase light emission and based
on the GFP signal with the use of FACS. Without the help of light-emitting proteins,
isolation of cell clones with high levels of induced target gene expression is difficult.
To maintain both the reporter and the chimeric transcriptional activator plasmid
constructs in the mammalian cell genome, different antibiotic selection genes need to
be included in the two plasmid DNAs. After cotransformation, cells are initially
grown in medium containing both antibiotics for two weeks. Cells that exhibited
basal levels of light emission indistinguishable from untransformed cells are collected
and propagated for three days without the addition of antibiotics. Then mifepristone
is added to the medium. After continuous culture for another 36 hours, the cell
population is analyzed with FACS for identification of cells with the highest level of
activated Ruc-GFP expression. These cells are collected and grown in the absence of
antibiotics. Cells isolated by the detectable marker based enrichment procedures are
expected to be genetically stable for months, which will be valuable in cell
implantation and in vivo therapeutic uses.
Currently, the monitoring of GFP signal in live animals is limited to structures
located close to the surface. This is due to the limited penetration of the excitation
wavelengths that are necessary to induce green fluorescence and due to the strong
scattering of fluorescence emission by the tissues. Successful visualization and
localization of GFP signal originating from transformed tissues in nude mice at a
depth of only 2.2 mm has been reported (Yang et al. 2000). Novel techniques, such
as two-photon laser scanning microscopy, may need to be applied to increase the
sensitivity and resolution of fluorescence monitoring in cells and in tissues.
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A similar two-plasmid-DNA-mediated, steroid-regulated, gene expression system
(UAS/TAXI) was constructed by Delort and Capecchi (1996). The principle of the
UAS/TAXI system is essentially the same as that of the promoter activation system as
described originally by O’Malley and colleagues as the “GeneSwitch” (Wang et al.
1994), with the exception of a few differences. Both systems are based on two
plasmids: the chimeric transcriptional activator plasmid which carries the fusion gene
of the GAL4 DNA binding domain, the truncated human progesterone receptor
hormone binding domain (hPR-HBD), and the herpes simplex virus protein VP 16
activation domain which encodes one fusion protein; the reporter plasmid carries a
transcriptional activator-dependent promoter-marker gene fusion construct which
contains repeats of GAL4 upstream response elements and a minimal synthetic
promoter (UAS) linked to the target gene. The differences between the two systems
are, in the activator plasmid of the UAS/TAXI system, the hPR-HBD has a deletion
of the 35 (rather than 42 as in “GeneSwitch”) carboxyl-terminal amino acids.
Further, in the chimeric transcription factor, the VP 16 acidic transactivation domain
contains residues 415-486 (rather than 411-487 as in “GeneSwitch”). In the reporter
plasmid constructs, the differences between the two systems are that there are five
(rather than four as in “GeneSwitch”) repeats of GAL4 upstream response elements
linked to a minimal promoter sequence from the Drosophila hsp70 gene (rather than
the adenovirus major late E1B TATA sequence as in “GeneSwitch”) in the
UAS/TAXI system. Also, in the UAS/TAXI reporter plasmid, the GAL4 DNA
binding domain spans residues 1-147, in contrast to 1-94 as in the promoter of the
“GeneSwitch” reporter plasmid. We have inserted the ruc-gfp marker gene into the
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UAS/TAXI system to create the reporter plasmid pUAS-rwc-g/p, and compared its
activation in the presence of the chimeric activator plasmid pTAXI and inducer drug
mifepristone in transient transformations (Fig. 3.7). Although the inducible gene
expression from the UAS/TAXI system was dependent on mifepristone, the
activation results we obtained were lower than the activation data with the
“GeneSwitch” system. The highest induction levels of Ruc-GFP expression obtained
using the UAS/TAXI system in cell culture experiments were merely five fold. In
addition, there was a lack of consistency in the levels of gene expression using the
UAS/TAXI system from one experiment to the next. We found no apparent optimal
concentration of mifepristone that gave the highest level of induction. In animal
experiments, we found that UAS/TAXI responded less well to the intraperitoneally
delivered mifepristone than when both plasmid DNAs were injected into the limb
muscles of nude mice (Fig. 3.7A-c). Based on these comparisons, we concluded that
the promoter activation system developed by O’Malley and colleagues (Wang et al.
1994) proved to be more applicable to our gene expression studies.
There may be numerous applications of the mifepristone inducible gene
expression system.

In gene therapy, constitutive expression of proteins such as

hormones and cytokines may not be desirable at all stages of therapeutic applications.
An inducible system will therefore provide the investigators and clinicians with the
ability to control both the temporal and spatial expression of the therapeutic proteins.
Besides controlling the expression of therapeutic proteins, the induction system can
also be used to regulate the expression of engineered chimeric proteins such as those
encoded by suicide genes, e.g. the artificial death switches (ADS) (MacCorkle et al.
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1998). Similar to the activation of other suicide genes such as the Herpes Simplex
Virus thymidine kinase gene, activation of ADS leads to cell death. Such suicide
genes can be included in gene therapy vectors and delivered to the organism. When
the therapy is satisfactory or its continuation is undesired to the host, the treatment
can be terminated by activating the expression of ADS proteins in the implanted
transformed cells to initiate the pre-programmed suicide process. In addition to its
clinical applications, the inducible system can also be enormously valuable in
transgenic animal studies. Many functional protein studies in transgenic animals,
such as investigating the role of developmentally regulated transcription factors, have
proven to be difficult due to perinatal lethality caused by uncontrolled nonphysiological over-expression of the gene-of-interest. However, a regulated gene
expression system can circumvent such a problem by only activating the expression
of a gene after the embryo or fetus reaches a certain developmental stage. Functional
studies on transforming growth factor (31 using the mifepristone regulated gene
expression system (Wang et al. 1999) have shown the usefulness of such strategies.
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CHAPTER FOUR
MIFEPRISTONE-REGULATED EXPRESSION OF RENILLA LUCIFERASEAEQUOREA GFP FUSION PROTEIN IN ALGINATE-ENCAPSULATED
MAMMALIAN CELLS
Abstract
The mifepristone-regulated transcriptional activation system provides a means to
exogenously control gene expression in transformed mammalian cells temporally and
spatially. To apply this system successfully in cellular implants into animals for
prolonged studies requires the encapsulation of the cells with a biocompatible
polymeric device. We used biocompatible calcium alginate/poly-L-lysine (PLL)
beads to provide immune protection for cells during cellular implantation. Using
Aequorea green fluorescent protein (GFP) as a marker, we monitored the growth and
proliferation of encapsulated cells over a long period of time, up to two and a half
months. Furthermore, to study regulated gene expression in encapsulated cells, a
Renilla luciferase-GFP (ruc-gfp) fusion gene was linked with a synthetic promoter
that is inducible in the presence of exogenously added mifepristone. We showed that
the ruc-gfp fusion gene expression in encapsulated mammalian cells is regulated in a
mifepristone dose-dependent manner. The highest induction by mifepristone occurs
at a final concentration of 250 nM. This induction reached a maximal level of
approximately 8-9 fold and lasted up to 37 hours after the initial addition of
mifepristone. From these results, we conclude that regulated protein expression from
alginate-encapsulated cells may provide a useful tool for designing cellular implantbased protein therapy in the future.
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Introduction
Many metabolic diseases are caused by a deficiency in the production of a key
protein. This can be temporarily corrected by injection of the missing protein.
However, such recombinant protein therapy can be costly for long-term treatment of
the disease. To address this problem, various somatic gene therapy strategies have
been developed to allow a sustained delivery of the therapeutic protein
(Vervoordeldonk and Tak 2001). These strategies include viral-based transgene
delivery, such as recombinant adenovirus (Schneider et al. 2002) and adenoassociated virus (rAAV) (Flotte et al. 1993; Murphy et al. 1997; Snyder 1999;
Kawada et al. 2002; Melo et al. 2002), and non-viral-based gene delivery, such as cell
transplantation (Grompe 1999; Musgrave et al. 2002). The main disadvantages of
virus-based long-term therapy are the associated risks. In fact, it has been reported
that long-term delivery of rAAV can be tumorigenic (Donsante et al. 2001). Cellbased therapy, on the other hand, has many advantages over viral-based therapy.
These advantages include a much higher carrying capacity of exogenous genetic
materials (such as with an artificial chromosome), a lower risk of transgene
integration into the host genome, a more stable therapeutic protein production, etc. A
major obstacle associated with cell-based therapy however, is the host immune
rejection of cellular implants. Genetic modifications of the donor cells have been
introduced to reduce host immune rejection (Cozzi et al. 2000; Dorling et al. 2000).
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In addition to genetic modifications, a more convenient and cost-effective method is
microencapsulation of cellular implants with biocompatible polymers (Uludag et al.
2000). The semipermeable polymer will protect cells from the host immune system,
but allow the passage of nutrients, oxygen, metabolic waste, and small therapeutic
proteins. Due to the biocompatible nature of the polymers, the recipient is not
required to be on immunosuppression medication. In addition to prevention of
immune rejection, microcapsules also provide a stable environment, and help to
contain the cellular implants in defined locations. The risk of uncontrolled spreading
of exogenous cells in the host therefore is greatly reduced. Upon completion of
therapy, the cell-containing microcapsules can be conveniently removed.
Biocompatible polymers used for cellular encapsulation can be divided into two
major groups: (1) carbohydrate polymers, including alginate (Lim and Sun 1980),
agarose (Scheirer et al. 1983), cellulose (Armeanu et al. 2001), glycosaminoglycan
(Orgill et al. 1998), and chitosan (Zielinski and Aebischer 1994); and (2) non
carbohydrate polymers, including AN69 (Kessler et al. 1991), 2-hydroxyethyl
methacrylate / methyl methacrylate (HEMA-MMA) (Dawson et al. 1987), polyethersulfone (PES) (Regulier et al. 1998), and poly-acrylonitrile-co-vinyl chloride
(Aebischer et al. 1996). Among these, alginate was the first and one of the most
widely used polymers for mammalian cell encapsulation. Alginate polymers are
9+

composed of guluronic acids and mannuronic acids polymerized by Ca . After the
formation of the alginate core, the polyanionic alginate bead is first coated with a
polycationic PEL membrane, and then with an outer layer of alginate. The diameter
of the spherical alginate-PLL microcapsules can be set to range from 200 to 2,000
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jam. The permeability of the alginate-PLL capsules can be modulated by varying the
concentrations of alginate and PLL. Transplantation of alginate-encapsulated cells
has helped to treat a variety of metabolic diseases, such as hyperbilirubinemia (Bruni
and Chang 1989), type I diabetes (Soon-Shiong 1999), and lysosomal storage
deficiency (Ross et al. 2000), either in animal models or in human patients.
In addition to microencapsulation, another possible safety feature of a cell therapy
system is that the transgene expression in the cellular implants can be regulated by an
inducible promoter, as has been shown by others (Zoltick and Wilson 2001). This
allows regulated expression of therapeutic proteins in a time and dose-controlled
manner. Unregulated delivery of therapeutic proteins, on the other hand, may
backfire and result in adverse metabolic consequences (Al-Hendy et al. 1996).
Inducible promoter systems, including the Tet-on system (Saitoh et al. 1998;
Hagihara et al. 1999) and the mifepristone system (Serguera et al. 1999) have been
introduced in encapsulated cells to control therapeutic gene expression. The
mifepristone-regulated promoter system (Wang et al. 1994) has three components: (a)
a plasmid carrying the expression cassette encoding a chimeric transcriptional
activator under the control of a constitutive promoter; (b) a plasmid carrying a
synthetic promoter derived from the yeast GAL4-binding sequence linked to a
therapeutic gene or a reporter gene; and (c) the inducer drug, mifepristone. The
presence of the inducer drug allows binding of the chimeric transcription factormifepristone complex to the inducible promoter to activate transcription. Using this
system, controlled gene-transfer studies have been successfully conducted in cell
cultures and in live animals (Burcin et al. 1999; Osterwalder et al. 2001; Terada et al.
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2001; Draghia-Akli et al. 2002). Although regulated gene expression from
encapsulated cells has been reported, no experiments have been conducted to study
mifepristone-induced gene expression in alginate-encapsulated cells. In this paper,
we utilized Renilla luciferase light emission and GFP fluorescence to investigate real
time gene expression in encapsulated cells. The kinetics of mifepristone dosedependent induction of the ruc-gfp fusion gene expression in encapsulated cells were
also examined in real time.
Materials and Methods
Plasmid Vector
The construction of the reporter plasmid pl7x4-TATA-rwc-g/p was described
previously (Yu et al. 2001). The chimeric transcriptional activator plasmid (PAP
CMV-GL914VPc’SV) was a gift from Dr. Y. Wang (Department of Cell Biology,
Baylor College of Medicine, Houston, TX). A retroviral shuttle vector, pLEIN,
carrying an EGFP expression cassette under the control of a constitutive 5 ’ LTR
promoter, was obtained from Clontech (Palo Alto, CA).
Tumor Cell Lines
COS cells (monkey kidney cells transformed by SV40 virus; ATCC, Rockville,
MD) were cultured in DMEM medium (Cellgro, Mediatech, Inc., Herndon, VA)
supplemented with 10% (v/v) FBS, 2 mM glutamine, and lx penicillin/streptomycin.
HT1080 human fibrosarcoma cells (ATCC, Manassas, VA) were cultured in F12
minimal essential medium (Cellgro, Mediatech, Inc., Herndon, VA) supplemented
with 10% FBS and lx penicillin/streptomycin.

Ill

Establishment of a Stably Transformed HT1080 Cell Line by Retroviral
Transduction
PT67 packaging cells (Clontech, Palo Alto, CA) were cultured in DMEM medium
supplemented with 10% (v/v) FBS. At 70% confluence, PT67 cells were transformed
with the pLEIN vector using the calcium phosphate precipitation method (Profection
Mammalian Transfection Systems, Promega, Madison, WI). Twelve hours after the
initiation of transformation, fresh medium was added. Retroviral supernatant fluid
collected from PT67 cells 48 hours post transformation was filtered through a 0.45
pm filter and added to target HT1080 cells. In addition, polybrene was added to a
final concentration of 4 pg/ml. The medium was replaced after 24 hours, and the
cells were selected with G418 at 400 pg/ml, increased stepwise over time to 1200
pg/ml in order to select stably transformed cells.
Alginate Encapsulation of Mammalian Cells
Alginate beads were prepared using an Inotech Encapsulator (Dottikon,
Switzerland) with a vibrating nozzle. A low viscosity alginate sodium salt (SigmaAldrich, St. Louis, MO) was used to produce beads. A detailed description of the
Encapsulator and protocols for alginate microencapsulation can be found elsewhere
(Serp et al. 2000). In brief, to produce <50 ml of encapsulated cells, 13 ml of 1%
alginate solution (1% sodium alginate, 10 mM MOPS, 0.85% NaCl) were mixed with
9.5 ml of cells suspended in MOPS washing buffer (10 mM MOPS, 0.85% NaCl).
Droplets of cells were dispersed into 225 ml (10 times the volume of alginate/cell
mixture) of Ca2+ polymerization solution (10 mM MOPS, 100 mM CaCf). After
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polymerization for 10 min, the beads were transferred into 50 ml of 0.05% PLL
(prepared with MOPS washing buffer) and stirred for 10 min. Then the beads were
washed with 100 ml of MOPS washing buffer for 1 min, and again with 150 ml of
MOPS washing buffer for another 5 min. The excess washing buffer was aspirated.
Then 50 ml of 0.03% alginate solution (0.03% sodium alginate, 10 mM MOPS,
0.85% NaCl) were added to the beads and incubated for 5 min with stirring. The twostep washes with MOPS were repeated again and the excess washing buffer was
aspirated. Fresh supplemented DMEM culture medium was added to the beads,
which were then aliquoted into 6-well titer plates, and kept in the tissue culture
incubator at 37 °C, 100% humidity, and 5% CO2.
Determination of Mifepristone-Dose Dependency and Kinetics of Inducible RucGFP Expression in Encapsulated COS Cells
COS cells (5 x 106) were seeded in three 10 cm culture dishes and grown to ~70%
confluence in supplemented DMEM medium. The cells were then transiently
transformed with both plasmids of the inducible promoter system using the calcium
phosphate precipitation method. To transform cells in one 10 cm dish, 40 pg of
reporter plasmid pl7x4-TATA-n/c-g/p and 2 pg of the chimeric transcriptional
activator plasmid PAP CMV-GL914VPc’SV were used. Fifteen hours after
transformation, the cells were harvested and encapsulated in alginate-PLL beads.
Twelve hours after encapsulation, mifepristone was added to the aliquot of the
encapsulated cells to a final concentration of 0, 125, 250, 500, 1000, 4000, 16000,
32000, or 64000 nM to initiate induction of gene expression. Twenty-four hours after
the addition of mifepristone, the encapsulated cells were assayed for luciferase
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activity and monitored for GFP fluorescence to determine mifepristone dosedependence at the above molar concentrations.
To determine the kinetics of the inducible promoter system in encapsulated cells,
a fixed final concentration of 250 nM of mifepristone was used to induce
transcriptional activation. For each experimental culture, one culture without
mifepristone was used as a negative control. The cell transformation and
encapsulation steps were carried out as described above, except that the luciferase
activity and GFP fluorescence in encapsulated cells were examined at 0, 6, 9, 12, 15,
18, 21, 24, 27, 28, 31, and 34 hours after the addition of mifepristone.
Luciferase Assays
The culture medium in each well was removed by aspiration and replaced with 1
ml of luciferase assay buffer (0.5 M NaCl; 1 mM EDTA; and 0.1 M potassium
phosphate, pH7.4) to which was added 1 pg of coelenterazine substrate from a 0.5
pg/pl methanol stock solution. The luciferase light emission from alginateencapsulated cells was determined using an Argus 100 Low Light Video Camera
(Hamamatsu Instruments, Hamamatsu, Japan) and recorded with Image-Pro Plus
software (MediaCybemetics, Silver Spring, MD).
Fluorescence Imaging
Determination of GFP expression in encapsulated cells was performed using
either a Leica MZ8 stereo fluorescence microscope or a Zeiss fluorescence
microscope, both equipped with a mercury lamp power supply and a GFP filter
(excitation at 470 nm). For the Leica microscope, images were captured using a
SONY DKC-5000 3 CCD digital camera and processed with the Adobe Photoshop
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5.0 software (Adobe Systems, San Jose, CA). For the Zeiss microscope, images were
captured with a conventional camera using 800° ISO color film.
Results
Encapsulation of Mammalian Cells in Alginate Beads
We first evaluated alginate-based mammalian cell encapsulation using HT1080
fibrosarcoma cells stably transformed with a retrovirus-encoded, enhanced gfp
construct. The number of cells encapsulated in the alginate beads can be manipulated
to be in the range of <50 to >500 cells per bead (data not shown). Typically, we
encapsulated 50-100 cells per bead. Initially, the cells were distributed throughout
the alginate beads immediately after encapsulation (Fig. 4.1 A). Over time, small
clusters of green fluorescent cells developed within the beads. During the next two
weeks, some clusters of cells predominantly outgrew other groups of cells (Fig. IB),
and formed large green fluorescent clusters. In alginate beads with a diameter of
>500 pm, the green fluorescent cells tended to cluster in spindle-shaped islands (Fig.
4.1B-C). In alginate beads with a diameter <200 pm, often the entire bead was filled
with a spheroid of green fluorescent cells (Fig. 4.2).
The alginate beads prepared in our experiments consisted of a calcium alginate
core, a PLL capsule, and an outer membrane of alginate. Without the PLL capsule,
the alginate beads were observed to break apart, starting at two and a half weeks after
encapsulation. Green fluorescent cells were observed to grow on the bottom of the
culture dish after falling out of the broken beads (data not shown). With the PLL
capsule, the alginate beads were much more stable. In most cases, very few cells
were released from the beads.
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Fig. 4.1. Alginate-PLL microencapsulation of HT1080 human fibrosarcoma cells
stably transformed with a GFP-encoding retroviral construct. Individual green
fluorescent cells were seen dispersed in the beads (A) immediately after
encapsulation when examined under a Leica fluorescence stereomicroscope equipped
with a mercury lamp and a GFP filter set. (B) Nine days after encapsulation, clusters
of green fluorescent cells emerged and outgrew the other originally encapsulated cells
as seen under the Leica microscope. (C) Twelve days post-encapsulation, multiple
large clusters of cells exhibiting green fluorescence were observed in the beads when
examined under a Zeiss fluorescence microscope. The sizes of these cell clusters
eventually reached a steady state. The encapsulated cells exhibited visible green
fluorescence for more than two and a half months (data not shown). The images were
taken under blue excitation light for green fluorescence and also in the presence of a
low level of background illumination to mark the location of the beads. (Bars = 2
mm).
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Fig. 4.2. Encapsulated cell viability analysis based on the intensity of GFP
fluorescence. HT1080 human fibrosarcoma cells were stably transformed with a
GFP encoding retroviral construct. Fifteen days after the beginning of encapsulation,
cells losing viability were shown to have dramatically decreased fluorescence
intensity (solid arrow), whereas strong fluorescence emission was observed in viable
cells when GFP was still actively expressed (dashed arrow; Bar = 2 mm).
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In vivo Viability ofAlginate-Encapsulated Mammalian Cells
We investigated the viability of mammalian cells in alginate-encapsulated beads
based on GFP fluorescence. Two weeks after encapsulation, we observed that some
large clusters of encapsulated cells were no longer fluorescent (as indicated by the
solid arrow in Fig. 4.2), whereas other cells remained strongly fluorescent (as
indicated by the dashed arrow in Fig. 4.2). Since the HT1080 fibrosarcoma cells
were stably transformed and were selected from a single clone, all of the cells should
have the same copy numbers of the gfp construct on their chromosome(s). Therefore,
it is reasonable to correlate weaker green fluorescence with lower cellular viability.
We found that, even after two to three months of culturing, the majority of the
encapsulated cells were fluorescent and therefore putatively viable (data not shown).
Mifepristone-Induced Ruc-GFP Reporter Expression in Encapsulated Cells
We evaluated the inducible gene expression system in encapsulated cells. COS
cells were transformed with both the reporter (ruc-gfp) and the chimeric
transcriptional activator plasmid constructs. The transformed cells were then
encapsulated in alginate-PLL beads. To obtain information about the mifepristonedose dependency of the inducible system, we first treated the encapsulated cells with
stepwise increasing concentrations of mifepristone. Luciferase-based photon
emission in the presence of the substrate coelenterazine was recorded to
quantitatively analyze the levels of activated gene expression. We found in our dose
dependency studies that a final concentration of 250 nM mifepristone resulted in the
highest level of induction (Fig. 4.3). In general, an approximately 7-8-fold induction
was seen when mifepristone was given in a final concentration between 250 nM and
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Fig. 4.3. Mifepristone dose-dependent activation of luciferase activity in
encapsulated cells. COS cells were transformed with both the reporter and the
chimeric transcriptional activator plasmids of the inducible promoter system. Fifteen
hours after transformation, the cells were encapsulated in alginate-PLL beads.
Various amounts of mifepristone were added to the beads twelve hours after
encapsulation to initiate the induction of ruc-gfp gene expression. Twenty-four hours
later, the encapsulated cells were analyzed for luciferase activity in the presence of
the substrate coelenterazine. A final concentration of 250 nM of mifepristone
resulted in the highest level of induced luciferase activity at approximately 8 fold.
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1000 nM. Excessive amounts of the inducer drug tended to inhibit rather than
promote gene activation. These data were very similar to what we had previously
reported in the inducible system in cultured mammalian cells (Yu et al. 2001).
In addition to dose-dependency, we also analyzed the kinetics of the inducible
gene expression system in encapsulated cells. Since we noted that a final
concentration of 250 nM of the inducer drug would result in the highest level of
induction, we therefore used that concentration of drug to determine the kinetics of
induced gene expression. Induced luciferase activity was shown to increase in a
linear fashion during the first twenty-four hours after the addition of mifepristone, but
the rate slowed somewhat thereafter (Fig. 4.4A). Thirty-seven hours after the initial
induction, an approximately 8-9-fold induction of gene expression was observed (Fig.
4.4A-B). In the absence of the inducer drug, there was a <l-fold increase in
luciferase activity, which could be caused by non-specific binding of endogenous
transcription factors to the synthetic promoter. At the 37 h induction time point, we
qualitatively assayed GFP fluorescence and found weak induced GFP signal in small
clusters of cells, but no GFP fluorescence in the negative control cells without
mifepristone addition (data not shown).
Discussion
In the present study, we have demonstrated that the long-term viability of
alginate-PLL encapsulated mammalian cells can be easily monitored in a noninvasive manner based on GFP fluorescence. We also showed that using a lightemitting fusion gene (ruc-gfp) construct, mifepristone-activated gene expression in
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Fig. 4.4. Kinetic analysis of the inducible promoter system in encapsulated cells.
COS cells were transformed with both the reporter and the chimeric transcriptional
activator plasmids of the inducible promoter system, as was done in the mifepristone
dose-dependent experiment. Fifteen hours after transformation, the cells were
encapsulated in alginate-PLL beads. A final concentration of 250 nM of mifepristone
was used to initiate transcriptional activation twelve hours after the beginning of
encapsulation. The control experiments were carried out identically except there was
no addition of the inducer drug mifepristone. The kinetics of the induced gene
expression in encapsulated cells were investigated based on assaying luciferase
activity at different time points (Panel A). Quantitative analysis of
luciferase/coelenterazine photon emission was performed using a Hamamatsu
Argus 100 Low Light Imager. Panel B shows a pseudo-colored image of total photon
emission collected over 1 min using experimental and control samples at the 37-hour
time point. The left side shows the strong luminescence activity in the presence of
mifepristone induction, and the dashed circle on the right indicates the margin of the
well of the titer plate where the parallel control experiment was carried out in the
absence of mifepristone.
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microencapsulated cells could be quantitatively and qualitatively examined in real
time.
To develop a successful gene therapy protocol, one needs to satisfy the following
minimal requirements: a long-term delivery of the therapeutic protein; a regulatable
therapeutic protein level at desired times; and a minimization of immune rejection of
the gene therapy delivery system. In our present study, we focused on developing a
cell therapy system that could potentially address some of the above requirements,
namely; (1) use of an artificially inducible promoter system that can be activated by
the presence of an exogenously added drug, and (2) the encapsulation in
biocompatible alginate polymers of the mammalian cells carrying the therapeutic
genes.
In our experiments, we found that the long-term viability of encapsulated cells in
alginate beads could be determined by imaging GFP fluorescence in real time. This
non-destructive method is preferable to other methods of determining cell viability
such as conventional propidium iodide staining, trypan blue exclusion, or calcein
fluorescence labeling (Live/Dead TM Viability/Cytotoxicity Assay, Molecular
Probes, Eugene, OR). In particular, an advantage of the GFP-based method over
calcein fluorescence labeling is that the later method requires the exogenous delivery
of calcein probes for fluorescence, whereas the detection of GFP activity is based on
the fluorescence emission of an endogenous protein. It has been reported that cells
encapsulated in the central core of the beads tend to be less labeled using calcein
fluorescence (Zhou et al. 1998), which may result in false conclusions. It is important
to point out that GFP is rather stable with a half-life of approximately 26 hours, this
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may limit its use as a marker for short-term viability analysis, but long-term cell
survival can be monitored based on GFP expression. It has been demonstrated that
GFP fluorescent light extinction can be used as an indicator of cell apoptosis and
necrosis (Steff et al. 2001; Strebel et al. 2001). GFP-based cell viability assays have
been developed to facilitate cryobiological applications (Elliott et al. 2000). Using
GFP as a viability biomarker of encapsulated cells as shown in our experiments
clearly demonstrates its powerful application potential. A word of caution, the GFPbased cell viability assay can only be used to evaluate cells that have been stably
transformed by a gfp construct and which are from the same clone. In fact, even in
stably transformed cells, part of or the entire integrated exogenous construct can be
recombined out of the chromosome to form extrachromosomal arrays. Loss of
extrachromosomal arrays may also cause the loss of GFP fluorescence. In our
experiments, we applied constant G418 selection pressure to ensure the stability of
the construct. In transient transformations, on the other hand, a lower level of
fluorescence signal could be caused by variation in copy numbers of the transformed
gfp construct, which therefore may lead to false conclusions.
We found that the mifepristone-induced transcriptional activation in encapsulated
cells is less robust than free cells in tissue cultures. The highest level of induction
based on monitoring luciferase activity is approximately 8-9 fold, which is
considerably lower than the ~30 fold induction seen in free cell cultures (Yu et al.
2001). This could be explained by the limited access of mifepristone to the
encapsulated cells. Since we used transiently transformed cells in our experiments,
we did not test the induced luciferase activity beyond 37 hours after mifepristone
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addition. In the future, a cell line stably transformed with both the reporter and the
chimeric activator plasmids of the inducible system needs to be established. Using
such a cell line, a higher level of induced transgene expression may be achieved when
longer exposure times and multiple doses of mifepristone are given.
Although the alginate-based cell encapsulation is considered to be biocompatible,
certain components of the alginate beads, such as mannuronic acid polymers, may
provoke a pro-inflammatory response by host monocytes (Flo et al. 2000; King et al.
2001). The recruitment and growth of pericapsular macrophages significantly limits
the survival of encapsulated cells in clinical transplantation (De Vos et al. 1993). To
address this problem, 15-deoxyspergualin, a macrophage inhibitor, has been used to
prolong the survival of encapsulated grafts against macrophages (Hsu et al. 1999).
The generation of antibodies against capsules with a high content of mannuronic acid
has also been reported (Kulseng et al. 1999). The guluronic acid-rich alginate, on the
other hand, was shown to be much less capable of triggering an antibody response
(Kulseng et al. 1999), and therefore is more stable following implantation.
In the future, to mimic the design of polymer-cell-encapsulation-based artificial
organs, we plan to analyze the secretion of Ruc-GFP fusion protein from
encapsulated cells. A DNA sequence encoding a signal peptide will be inserted in
frame at the 5’ end of ruc-gfp fusion gene. Real-time protein secretion analysis from
mammalian cells based on luciferase has been documented (Liu et al. 2000). Similar
experiments will be performed using encapsulated cells. Furthermore, the
mifepristone-induced gene expression from encapsulated cells will be ultimately
evaluated in animal models. For example, the alginate-encapsulated cells will be

128

implanted in the subarachnoid space to test mifepristone-induced endorphin secretion
into cerebral spinal fluid for potential pain-control therapy, as has been demonstrated
in other similar systems (Saitoh et al. 1995; Ishii et al. 2000). Encapsulated cells
could also be implanted into the intraperitoneal space to assay the release of
therapeutic proteins into the blood for treatment of metabolic diseases, such as
obesity which has been treated in animal models by delivering regulated levels of
leptin protein (Meinders et al. 1996; Muzzin et al. 1996). These experiments, if
successful will help to advance the clinical application of encapsulated cell therapy.

129

CHAPTER FIVE
CONCLUSIONS AND FUTURE DIRECTIONS
Conclusions
In this study, we described for the first time the monitoring of regulated gene
expression from a mifepristone-induced promoter activation system in real time.
Non-invasive imaging of gene expression was possible using the light-emitting RucGFP fusion protein. This allowed both qualitative and quantitative measurement of
gene activities. We described the construction of a reporter plasmid that carries a
mifepristone-regulated synthetic promoter linked to a ruc-gfp fusion gene encoding a
fusion protein with both Renilla luciferase and GFP activities. This plasmid was
cotransformed with the chimeric transcriptional activator plasmid into COS cells.
The induction of ruc-gfp fusion gene expression was monitored following the
exogenous addition of mifepristone. We showed that there was nearly a 30-fold
induced increase of ruc-gfp marker gene expression in cell cultures. We showed that
the mifepristone-activation of gene expression is dose-dependent and is strictly
regulated by the chimeric transcriptional activator protein.
The significance of our findings is that the establishment of this rapid and
noninvasive method of monitoring inducible gene expression in cell cultures will aid
investigators in developing imaging procedures to continuously visualize gene
function in developing organisms in real time. Also our system will facilitate the in
vivo localization of therapeutic proteins in animal models and perhaps eventually in
human subjects throughout the course of a gene therapeutic modality.
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We also, for the first time, demonstrated and quantified mifepristone-controlled
protein expression in alginate-microencapsulated cells utilizing the Ruc-GFP fusion
protein. In addition, we demonstrated that the long-term viability of alginate-PLL
encapsulated mammalian cells can be easily monitored in a non-invasive manner
based on GFP fluorescence.
Future Directions
The combined application potential of the mifepristone-induced gene expression
activation system and the non-invasive monitoring of induced gene expression is
enormous. In gene therapy, the mifepristone-regulated system may provide the
investigator and clinician with a means to control the expression of the therapeutic
proteins, such as hormones and cytokines, in levels similar to physiological
conditions. By directly linking the expression of the light-emitting Ruc-GFP fusion
protein with the expression of target therapeutic proteins, the in vivo levels of the
inducibly expressed therapeutic proteins can be modulated in real-time. Besides
controlling the expression of therapeutic proteins, the induction system can also be
used to control the expression of engineered chimeric proteins such as those from
suicide genes, for example, the artificial death switches (MacCorkle et al. 1998).
These inducible suicide gene systems may provide another level of safety in future
clinical applications of gene therapy. The termination of therapeutic protein
expression can be indirectly monitored in real time based on Ruc-GFP light
extinction. In addition to its clinical applications, the inducible system can also be
enormously valuable in basic transgenic animal research. Since mifepristonedependent gene expression can be induced in either transgenic embryos or adult
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animals in vivo, functional studies of target proteins can be conducted easily with the
help of the light-emitting Ruc-GFP fusion protein upon reaching specific stages of
development or aging. Finally, it would be of great importance to design an efficient
inducible protein secretion system in microencapsulated cells. The induced target
protein secretion could be monitored and modulated in real-time with the aid of lightemitting proteins. A better understanding of inducible expression and the secretion of
therapeutic proteins by encapsulated cells will facilitate future clinical applications.
Ultimately, such microencapsulation-based recombinant cell therapy could even be
developed to mimic biocompatible artificial organs.
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APPENDIX
Lists of Buffers and Solutions
Buffer for Agarose Gel Electrophoresis
1 x Tris acetate buffer (TAE): 40 mM Tris-acetate, 1 mM EDTA
6 x Gel-loading buffer: 0.025% bromophenol blue, 0.25% xylene cyanol, 40% (w/v)
sucrose in water
Bacteria Culture Medium
Luria-Bertani (LB) medium: 1% Bacto tryptone, 0.5% yeast extract, and 1% NaCl;
autoclave to sterilize
LB agar plate: LB medium with 1.5% granulated agar
Brain heart infusion (BHI) medium: 3.7% BHI.
Note: All media were sterilized by autoclave at 10 lb/in2 and 220 °F for 20 minutes.
Reagents for Preparation of Competent E. coli (Heat Shock Method)
SOB medium: 2% Bacto tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KC1,
and 10 mM MgSO^ autoclave to sterilize
SOC medium: SOB medium with 20 mM glucose
TB washing buffer: 10 mM Pipes, 55 mM MnCh, 15 mM CaCh, and 250 mM KC1.
Note: pH is adjusted to 6.7 before the addition of MnCb.
Reagents for Preparation of Competent E. coli (Electroporation Method)
SOB medium
SOC medium
HEPES buffer: ImM, pH 7.0
Glycerol washing solution: 20%
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Glycerol storage solution: 10%
Plasmid Purification Solutions (Alkaline Lysis Method)
Solution I: 50 mM glucose, 25 mM Tris-Cl, pH 8.0, and 10 mM EDTA
Solution II: 0.2 mM NaOH and 1% SDS (prepared fresh before use)
Solution III: 3 M potassium acetate and 5 M acetic acid
RNase AMO mg/ml in 1 mM Tris-Cl buffer, pH 7.5
Ammonium acetate solution: 10 M stock solution
Tris-saturated phenol: phenol covered with a layer of Tris-Cl buffer, pH 8.0
Chloroform and isoamyl alcohol mixture (24:1): mix chloroform and isoamyl alcohol
in 24:1 (v/v) ratio and saturate with a layer of Tris-Cl buffer, pH 8.0
Plasmid Purification Solutions (QIAfilter Maxi Prep Method)
Buffer PI (resuspension buffer): 50 mM Tris-Cl, pH 8.0, 10 mM EDTA, 100 pg/ml
RNase A, stored at 4 °C
Buffer P2 (lysis buffer): 200 mM NaOH, 1% SDS, stored at room temperature
Buffer P3 (neutralization buffer): 3 M potassium acetate, pH 5.5, stored at 4 °C
Buffer QBT (equilibration buffer): 750 mM NaCl, 50 mM MOPS, pH 7.0, 15%
isopropanol, 0.15% Triton X-100
Buffer QC(washing buffer): 1 M NaCl, 50 mM MOPS, pH 7.0, 15% isopropanol
Buffer QF (elution buffer): 1.25 M NaCl, 50 mM Tris-Cl, pH 8.5, 15% isopropanol
Plasmid Purification Solutions (GENECLEANMethod):
Nal: 6 M, pH 6-7.4
Glassmilk
New Wash solution: a solution containing NaCl, Tris, EDTA, and ethanol
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TE Buffer
10 mM Tris-Cl, pH 8.0, 1 mM EDTA
SupplementedDulbecco's Minimum Essential Medium (DMEM)
DMEM, 10% fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, 100
pg/ml streptomycin
Supplemented RPMI1640 Medium
RPMI1640 medium, 10% fetal bovine serum, 2 mM glutamine, 100 units/ml
penicillin, 100 jug/ml streptomycin
Phosphate Buffered Saline (pH 7.4)
58 mM Na2HP04, 17 mM Na^PCU, 68 mM NaCl. Filter through a 0.2 pm filter to
sterilize. Store at 4 °C.
Buffers for Calcium Phosphate Precipitation Method (for DNA Transfer into
Mammalian Cells)
Calcium chloride: 2 M
HBS (HEPES-buffered saline) (2 x): 50 mM HEPES, 280 mM NaCl, 1.5 mM
Na2HP04, pH 7.1
DNAse-free water
Trypsin-EDTA solution (1 x); 0.05% (w/v) trypsin, 0.53 mM EDTA, prepared in 1 x
PBS buffer
Mammalian Cell Storage Medium
90% fetal bovine serum, 10% Dimethyl sulfoxide (DMSO) (0.2 pm filtered)
Bacterial Cell Storage Medium
Glycerol: 25%
Trypan Blue Cell Viability Assay Solution
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Trypan blue: 2% (0.2 pm filtered) in phosphate buffered saline
Luciferase Assay Buffer
0.5 M NaCl, 0.1 M potassium phosphate, 1 mM EDTA, pH 7.5
Lucif erase Lysis Buffer
125 mM Tris, pH 7.6, 0.5% Triton X-100
Antibiotic Stock Solutions
Ampicillin stock solution: 50 mg/ml in water, sterilized with 0.2 pm filter
Kanamycin stock solution: 50 mg/ml in water, sterilized with 0.2 pm filter
Chloramphenicol stock solution: 34 mg/ml in ethanol
Tetracycline stock solution: 7.5 mg/ml in ethanol
Penicillin / Streptomycin solution: 100 units/ml penicillin, 100 pg/ml streptomycin
Neomycin (G418) solution: 50 mg/ml in water
Alginate Microencapsulation Solutions
MOPS washing buffer: 10 nM MOPS, 0.85% NaCl
1.5% sodium alginate solution: 1.5% Na-alginate, 10 mM MOPS, 0.85% NaCl, pH
7.3-7.4

Polymerization solution: 10 mM MOPS, 100 mM CaCC
PLL-solution: 0.05% PLL (Molecular weight 15,000-30,000), 10 mM MOPS, 100
mM CaCl2
0.03% sodium alginate solution: 0.03% Na-alginate, 10 mM MOPS, 0.85% NaCl, pH
7.3-7.4
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